Midkine Attenuates Aβ Fibril Assembly and Amyloid Plaque Formation

Midkine Attenuates Aβ Fibril Assembly and Amyloid Plaque Formation | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Midkine Attenuates Aβ Fibril Assembly and Amyloid Plaque Formation Junmin Peng, Masihuz Zaman, Shu Yang, Ya Huang, Jay Yarbro, Zhen Wang, and 20 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4361125/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 21 Aug, 2025 Read the published version in Nature Structural & Molecular Biology → Version 1 posted You are reading this latest preprint version Abstract Proteomic profiling of Alzheimer's disease (AD) brains has identified numerous understudied proteins, including midkine (MDK), that are highly upregulated and correlated with Aβ since the early disease stage, but their roles in disease progression are not fully understood. Here we present that MDK attenuates Aβ assembly and influences amyloid formation in the 5xFAD amyloidosis mouse model. MDK protein mitigates fibril formation of both Aβ40 and Aβ42 peptides in Thioflavin T fluorescence assay, circular dichroism, negative stain electron microscopy, and NMR analysis. Knockout of Mdk gene in 5xFAD increases amyloid formation and microglial activation. Further comprehensive mass spectrometry-based profiling of whole proteome and aggregated proteome in these mouse models indicates significant accumulation of Aβ and Aβ-correlated proteins, along with microglial components. Thus, our structural and mouse model studies reveal a protective role of MDK in counteracting amyloid pathology in Alzheimer's disease. Biological sciences/Chemical biology/Proteomics/Protein–protein interaction networks Biological sciences/Structural biology/NMR spectroscopy/Solution-state NMR Figures Figure 1 Figure 2 Figure 3 Figure 4 Introduction Alzheimer's disease (AD), an irreversible and progressive neurodegenerative disorder, is the primary cause of dementia 1 . Genetic studies have revealed disease-specific genes (APP, PS1, PS2), high-risk genes (APOE4, TREM2, UNC5C), and a large number of risk loci associated with amyloid, tau, endocytosis, and immunity 2-4 . The dysregulation in the AD proteome within the brain is characterized by the accumulation of Aβ amyloid plaques 5 , tau neurofibrillary tangles 6 , and other aggregated proteins, including TDP-43 7,8 and U1 snRNP 9-13 . The recent FDA approval of lecanemab 14 , along with the promising Phase III trial results for Donanemab 15 , both being amyloid-targeting antibodies, lend support to the amyloid cascade hypothesis. However, the limited clinical benefits for AD patients suggest the presence of alternative disease mechanisms and imply that intervention at a late disease stage may be insufficient. Complementary to the genetic search for AD disease genes, we and others have performed large-scale proteomic profiling, uncovering consistent protein alterations in post-mortem AD brains across multiple large cohorts from various independent research groups 16-23 . This has highlighted the deregulation of numerous molecular pathways and protein co-expression modules. Remarkably, a subgroup of proteins is highly upregulated and show a strong correlation with Aβ levels since the early prodromal stage throughout disease progression, including midkine (MDK), pleiotrophin (PTN), netrin 1 (NTN1), netrin 3 (NTN3) and the HTRA1 serine protease 16,19 . Interestingly, these protein changes occur independently of their mRNA transcript levels, indicating post-transcriptional regulation 16,19 . Moreover, these Aβ-correlated proteins have been found in the detergent-insoluble, aggregated proteome, and within amyloid plaques in AD brains, as confirmed by mass spectrometry-based profiling and immunohistochemical analyses 13,24-27 . However, the direct involvement of these Aβ-correlated proteins in plaque formation and AD pathogenesis remains to be elucidated. The MDK/PTN family of cytokines, consisting of only two members 28 , are among the most closely Aβ-correlated proteins identified in proteomic analyses 16,19 . They are multifunctional heparin-binding factors that promote growth, survival, and migration of various cell types, including neurons and immune cells 28 . In 1993, MDK was reported to localize within the amyloid plaques associated with AD 29 . Preliminary studies suggest that MDK might directly interact with Aβ, displaying high affinity and potentially mitigating Aβ's toxic effects 30 , but the study had not received attention in the AD research field. Recent proteomic findings support MDK as a top candidate for modulating AD pathogenesis 16,19 , raising interest in fully exploring the role of MDK in AD. In this study, we have thoroughly characterized the impact of MDK on Aβ assembly in various assays including Thioflavin T, circular dichroism, negative stain electron microscopy (EM), and NMR, demonstrating that MDK protein inhibits the formation of Aβ fibrils. Importantly, the Mdk gene knockout (KO) in the background of 5xFAD mice leads to the amyloid increase and microglial activation. Further proteomic profiling of these mouse models reveals the accumulated Aβ and related proteins in the brain of the 5xFAD/KO mice, supporting MDK's protective role against amyloid pathology in AD. Results MDK, a top Aβ-correlated protein in human brain, attenuates Aβ fibril assembly Although MDK was identified within the senile plaques of AD patients by antibodies last century 29 , its role in AD has not been well investigated. Recent unbiased proteomic analyses have highlighted MDK as one of the top upregulated proteins highly correlated with Aβ 16 , 19 . To verify these findings, we re-analyzed an AD proteomic dataset comprising 111 human cases 16 , and performed Pearson correlation analyses of all identified proteins with Aβ and tau levels ( Extended Data Table 1 ). Strikingly, among more than 8,400 identified proteins, MDK shows the best correlation with Aβ levels (R = 0.90) (Fig. 1 a). In contrast, MDK displays a much weaker correlation with tau (R = 0.29), consistent with the idea that Aβ and tau do not strongly correlate during the progression of AD (R = 0.26). The presence of MDK in the plaque regions of the human brain was further confirmed through immunohistochemical (IHC) staining and immunofluorescent co-staining with Aβ peptides (Fig. 1 b, 1 c). Additionally, in the 5xFAD amyloidosis mouse model (also termed FAD for simplicity), which overexpresses mutant human APP and PSEN1 genes 31 , MDK accumulation was observed to be higher in FAD mice than in wild type (WT), corroborated by antibody-based detection of MDK in mouse plaques ( Extended Data Fig. 1 a, 1 b, 1 c). These findings not only reaffirm the strong Aβ-MDK correlation in human but also suggest the FAD mice as a valuable model for studying the role of MDK in AD pathogenesis. Given the previous reports that MDK protein directly binds to Aβ peptides 16 , 30 , we investigated its impact on Aβ fibrillization using various biophysical assays. Highly purified recombinant human MDK protein ( Extended Data Fig. 1 d) at concentrations ranging from 1 µM to 10 µM, was incubated with synthetic Aβ40 peptide at 5 µM. The fibrillization process was monitored by the fluorescence of thioflavin T (ThT), in which the fluorescence intensity increases upon binding with amyloid fibrils 32 . As anticipated, in the absence of MDK, Aβ40 displayed a time-dependent increase in fibrillization, with increased lag time and decreased ThT fluorescence intensity in a dose-dependent manner (Fig. 1 d). We further turned to the AmyloFit software 33 to determine effects of MDK on the microscopic steps during the aggregation of Aβ. The best fit revealed that MDK negatively impacts Aβ40 secondary nucleation rate constant ( k 2 ) and elongation constant ( k + ), as both log 2 ( k 2 ) and log 2 ( k + ) values show a linear decrease with increasing MDK concentrations (Fig. 1 e, Extended Data Fig. 1 e, 1 f). Following a 24 h incubation, far UV circular dichroism (CD) analysis of the Aβ40 samples confirmed the inhibitory effect of MDK on Aβ40 fibrillization. Aβ40 in absence of MDK initiated from unstructured random coil confirmation (0 h) to β-sheet structure (24 h). However, in the presence of MDK (10 µM) Aβ40 essentially retained into the unstructured confirmation like monomers (Fig. 1 f). We extended this study to synthetic Aβ42 peptide, yielding similar outcomes (Fig. 1 g, 1 h, 1 i, Extended Data Fig. 1 g). Moreover, the Aβ40/Aβ42 samples, with and without MDK, were examined using negative stain EM analysis (Fig. 1 j, 1 k). Amyloid fibrils were observed as the end-point aggregates of samples of Aβ40/Aβ42 peptide (5 µM) alone. In contrast, the presence of high concentration of MDK (10 µM, 2:1 molar ratio) produced some nonfibrillar aggregates, demonstrating MDK's potential to inhibit Aβ fibril formation effectively. It is important to note that MDK alone does not fibrillate under similar conditions as confirmed by ThT binding assay, far UV CD, and negative stain results ( Extended Data Fig. 1 h, 1 i, 1 j). Together, these results suggest that midkine is inhibiting the formation of amyloid fibrils in vitro . In spite of the inhibition effect of MDK on Aβ assembly, we observed that Aβ could still assemble as fibrils in the presence of lower MDK concentrations, such as a 1:1 molar ratio, and subsequently examined the Aβ42 fibrils under this condition using negative stain and immunogold electron microscopy. Although the resolution was low, the Aβ42 fibrils appeared to be surrounded by protein molecules ( Extended Data Fig. 2 a). As recombinant Aβ fibrils assemble differently from endogenous Aβ filaments found in human brains 34 – 38 , we further investigated the presence of MDK in Aβ fibrils extracted from human AD brains. Immunogold negative stain EM with the MDK antibodies revealed that MDK molecules are clustered around these Aβ fibrils ( Extended Data Fig. 2 b). Moreover, we utilized the AlphaFold2-multimer prediction tool 39 to hypothesize possible Aβ-MDK interacting interfaces, suggesting that the N-terminus of Aβ (residues 1–12) might interact with the C-terminus of MDK (residues 74–80 and 84–89) ( Extended Data Fig. 2 c, 2 d). To further confirm the effect of MDK on Aβ fibrillization, we acquired 1 H- 15 N HSQC NMR spectra of 15 N-labeled monomeric Aβ40 (10 µM) with MDK titration (0, 5, and 10 µM, Fig. 2 a). Reference spectra were acquired prior to incubation, with amide cross peaks assigned to specific residues 40 . After 48 h, a notable disappearance of cross peaks suggested Aβ40 peptide fibrillization. Remarkably, with MDK co-incubation at varying concentrations, the cross peaks re-appeared although at reduced intensities. As the HSQC cross peak intensities correlate with monomeric Aβ concentration 41 , we quantified the cross peak intensities for each residue (Fig. 2 b), and calculated the averaged percentage relative to the pre-incubation reference of Aβ40. The MDK addition (5 µM and 10 µM) rescued the cross peak intensities from 0.9 ± 0.2% to 38.3 ± 1.1% and 38.1 ± 0.9%, respectively (Fig. 2 c). We also observed a similar impact of MDK on Aβ42 fibrillization using a protocol of 24 h incubation (Fig. 2 d). However, the same concentrations of MDK were less effective in recovering Aβ42 cross peaks compared to Aβ40 (Fig. 2 e, 2 f). For example, the MDK addition (5 µM and 10 µM) retrieved the cross peak intensities from 4.8 ± 0.5% to 12.8 ± 0.8% and 21.8 ± 0.8%, respectively. This aligns with our ThT, CD and negative stain EM data, supporting the notion that Aβ42 is more aggregation prone than Aβ40 37 . In summary, our comprehensive biophysical characterization strongly demonstrates that MDK can modulate Aβ fibrillization in vitro. Genetic deletion of Mdk gene in FAD mice increases amyloid plaques and microglial activation. To investigate the role of MDK in Aβ fibrillization in vivo, we generated a mouse model with an Mdk gene knockout by CRISPR-mediated deletion of 23 base pairs in exon 3 of the mouse genome (Fig. 3 a). The deletion was confirmed through genome sequencing and PCR analysis (Fig. 3 b), with the absence of MDK protein verified by western blot analysis (Fig. 3 c). We crossbred this knockout line with the FAD mice to produce offspring that were either FAD mice with or without the Mdk knockout. The Mdk knockout resulted in a marked increase in Aβ levels in the cortex of 12-month-old mice brains, as shown by western blot analysis (Fig. 3 c). Further, ELISA analysis indicated elevated accumulation of both Aβ40 and Aβ42 peptides in the brain lysate (Fig. 3 d). These biochemical findings indicate that Mdk gene knockout contributes to the increased accumulation of two major Aβ species in the FAD genetic background. Next, we characterized the FAD/KO mice through immunostaining to evaluate the effects of Mdk deletion on plaque formation and microglial activation in the brain. As anticipated, Mdk knockout resulted in increased plaque density and area in the cortex of 12-month-old mouse brains (Fig. 3 e), which was accompanied by heightened microglial activation, evidenced by the rise in microglia density and area (Fig. 3 f). In subsequent immunofluorescence staining studies, amyloid plaques detected by the Aβ antibody were found to highly colocalize with MDK protein in FAD mice, and the MDK staining was absent in the knockout mice (Fig. 3 g). Additional co-staining with IBA1, a protein marker for microglia 42 , 43 , revealed a significant accumulation of microglia around the plaque areas (Fig. 3 g), in agreement with the observed increase in microglial density and area in the FAD/KO mice. These results underscore that Mdk gene knockout leads to enhanced plaque formation and microglial activation in the FAD mouse model. To understand the impact of Mdk knockout in the FAD mice at the molecular level, we analyzed the cortical brain proteome across four genotypes: WT, KO, FAD, and FAD/KO (Fig. 4 a, 4 replicates per genotype). Employing a refined tandem-mass-tag coupled with two-dimensional liquid chromatography and tandem mass spectrometry (TMT-LC/LC-MS/MS) platform 13 , 44 – 46 , we identified 113,297 peptides, corresponding to 9,531 proteins (8,365 genes) with false discovery rate (FDR) below 0.01, which were quantified across all these samples ( Extended Data Tables 2–3 ). After correcting sample loading bias, principal component analysis (PCA) and clustering analysis clearly separate distinct mouse groups, indicating the high quality of the proteomic data (Fig. 4 b, Extended Data Fig. 3 a- 3 b). As expected, MDK protein levels were elevated in FAD mice compared to WT and reduced to noise levels in knockout mice (Fig. 4 c). In FAD mice, Mdk deletion led to a significant increase of Aβ peptide levels (Fig. 4 c). To identify the differentially expressed proteins (DEPs) among the four genotypes, we performed an ANOVA analysis using a previously reported method 16 with two criteria: (i) a P-value of less than 0.05, and (ii) a log2 fold change (FC) greater than twice the standard deviation (2 SD) in any of the three pairwise comparisons: WT vs KO, FAD vs WT, or FAD/KO vs FAD ( Extended Data Fig. 3 c). Following this analysis, a total of 876 DEPs were accepted ( Extended Data Table 4 ), with a final FDR below 0.1 as determined by permutation analysis 47 . We then classified these DEPs into four whole proteome clusters (WPCs) using the weighted gene co-expression network analysis (WGCNA) 48 , followed by pathway enrichment analysis (Fig. 4 d, Extended Data Tables 4–5 ). In detail, WPC1 ( n = 460) exhibits a gradual increasing trend across the four genotypes from WT, KO, FAD to FAD/KO. This cluster includes Aβ and Aβ-correlated proteins 16 , such as Ntn1, Ptn, Clu, and Col25a1, as well as some marker proteins for microglia and astrocytes: Trem2, Ctss, Olfml3, Csf1r, Itgb5, Gfap, Aqp4, Pla2g7, Gja1, and Slc1a3 49,50 ( Extended Data Fig. 3 d), and it is enriched in four representative pathways: APP metabolic process, microglia activation, astrocyte activation and lipid catabolic process (Fig. 4 e, Extended Data Table 6 ). In contrast, WPC2 ( n = 229) shows notable decrease along the four genotypes, related to the pathways of calcium ion transmembrane transport, vesicle-mediated transport in synapse, neurotransmitter secretion, cognition, and G protein-coupled glutamate receptor signaling. Interestingly, this cluster includes the AD risk gene/protein Bin1 that regulates calcium homeostasis and neuronal excitability 51 , 52 . In addition, both WPC3 ( n = 84) and WPC4 ( n = 103) display effects of Mdk knockout that are independent of the FAD genetic background. Proteins in WPC3 decrease in Mdk KO mice and are enriched in four major pathways: neuron fate commitment, Schwann cell differentiation, myelination, and sphingolipid binding (Fig. 4 e, Extended Data Table 6 ). For instance, the cluster contains Pou3f1 (also known as Oct-6), which is a major downstream effector of cAMP in Schwann cells and a key transcription factor for myelination in the peripheral nervous system 53 , 54 . WPC4 primarily consists of proteins that are significantly upregulated due to Mdk knockout, enriched in the pathways of signaling receptor ligand precursor processing, neuropeptide signaling pathway, dendrite terminus, secondary active transmembrane transporter activity and GDP binding. For example, prohormone convertase 1 (Pcsk1) is a critical endopeptidase required for the processing of neurotransmitters and hormones 55 . Overall, the protein alterations found in WPC3 and WPC4 likely reflect the developmental function of midkine, implicating a pleiotropic impact of Mdk knockout. Nevertheless, within WPC1, we observed a distinct increase in Aβ and Aβ-correlated proteins, along with the activation of microglia and astrocytes, supporting that Mdk knockout exacerbates pathological severity. Furthermore, we validated the enhanced pathology in FAD/KO mice by profiling the detergent-insoluble, aggregated proteome in both FAD and FAD/KO mice, identifying 131,400 peptides from 9,411 unique proteins (8,236 genes, Fig. 4 f, Extended Data Table 7 ). After performing quality control analyses, such as normalization and PCA ( Extended Data Fig. 3 e, 3 f), we found that 450 DEPs were elevated in the aggregated proteome of FAD/KO mice compared to FAD mice ( Extended Data Fig. 3 g, Extended Data Table 7 ). Remarkably, the FAD/KO mice showed an accumulation of Aβ and other plaque-associated proteins in the aggregated proteome relative to FAD mice. A heatmap highlights some of these proteins, consistently detected in both the whole and aggregated proteomes, including Ntn1, Apoe, Aqp4, Ptn, Clu, Sulf2, and Col25a1 22 (Fig. 4 g, 4 h). In summary, the knockout of Mdk gene within the FAD mice resulted in an increase in Aβ and Aβ-associated proteins, amyloid plaque formation, and microglial activation. This was substantiated through experiments of western blotting, ELISA, immunostaining of brain tissues, and extensive proteomic profiling of both the whole and aggregated proteomes in the brain. Discussion Recent proteomics studies of Alzheimer's disease (AD) brains have identified a core set of proteins, including MDK, PTN, NTN1, NTN3, and SFRP1, that share several characteristics: (i) a high correlation with Aβ throughout AD progression; (ii) a prominent presence in the aggregated proteome; and (iii) enrichment in amyloid plaques 16 , 19 .However, the role of most of these proteins in AD pathogenesis remains underexplored. We focused on MDK for its potential impact on Aβ fibril assembly in vitro and amyloid plaque development in vivo. Our findings show that MDK disrupts Aβ fibril assembly, and its genetic deletion exacerbates plaque accumulation in the FAD mouse model. Considering the extended prodromal period before clinical AD onset, early Aβ accumulation may activate compensatory mechanisms to mitigate Aβ toxicity. Our research indicates that MDK could be one such factor, offering protective effects against Aβ-induced toxicity and contributing to resistance against amyloid pathology. MDK protein influences the fibrillation of Aβ40 and Aβ42 peptides, primarily through its inhibitory actions on the elongation of Aβ filaments ( k + rate constant) and the secondary nucleation phase of fibrillation ( k 2 rate constant). This influence is demonstrated by AmyloFit analysis of ThT fluorescence data, an approach previously used to study how inhibitors affect specific microscopic steps during the Aβ aggregation 33 , 41 , 56 . Several other proteins, such as the DNAJB6 and Brichos molecular chaperones, have been found to interfere with Aβ fibrillation through primary and secondary nucleation mechanisms 57 , 58 , whereas monomeric α-synuclein can block the secondary nucleation of the Aβ fibrils rather than primary nucleation 59 . Similar to monomeric α-synuclein, MDK might interact with Aβ oligomers rather than Aβ monomer, suppressing the Aβ fibrillation through inhibiting the secondary nucleation. Investigating the Aβ-MDK interaction at an atomic level by cryogenic electron microscopy in future studies will provide more mechanistic insights and could be important for rational design of effective therapeutic strategies in AD pathogenesis. While Mdk knockout's impact on amyloid accumulation in the FAD model can be attributed to its inhibitory effect on Aβ assembly, the Mdk knockout may have a pleiotropic effect. We observed an upregulation of PTN, another member of the midkine/pleiotrophin family. As PTN might have similar function to MDK, this upregulation could act as a compensatory mechanism mitigating the effects of MDK loss on amyloid formation. In addition, MDK has reported to interact with various membrane receptors, including PTPζ (a transmembrane tyrosine phosphatase) 60 , LRP-1 61 , integrins (α6β1 and α4β1) 62 , Neuroglycan C 63 , ALK (anaplastic lymphoma kinase) 64 , and Notch-2 65 , regulating development, cell migration and inflammation during brain injury 28 . Although the role of most of these MDK receptors in AD remains underexplored, LRP-1 is a receptor of the AD risk factor APOE, which regulates lipid hemostasis in AD development 66 . In our proteome analysis of Mdk KO mice, although there were no significant changes in the protein levels of these known MDK receptors, we did observe alterations of a subset of proteins (WPC3 and WPC4) resulting from the knockout of Mdk gene, independent of the FAD genetic background. These perturbed proteins might influence amyloid pathology. Nevertheless, our results reveal a potential role of MDK as a resilience factor in the early stage of developing amyloid pathology, offering a promising avenue for therapeutic intervention against the disease's progression. Declarations Acknowledgments We thank Dr. Ines Chen for critical readings and comments. We also thank St. Jude Shared Resources and Core Facilities, including Protein Technology Center, Biomolecular NMR Center, Cryo-electron Microscopy and Tomography Center, Cell and Tissue Imaging Center, Animal Research Center, Center for Advanced Genome Engineering, and Center for Proteomics and Metabolomics. This work was partially supported by the National Institutes of Health grants R01AG053987 (J.P.), RF1AG064909 (G.Y. and J.P.), RF1AG068581 (J.P.), U19AG069701 (J.P.), P30CA021765 and the ALSAC foundation. The Banner Sun Health Research Institute Brain and Body Donation Program was supported by the National Institutes of Health grants U24NS072026 (T.G.B), P30AG019610(T.G.B), P30AG072980, the Arizona Department of Health Services, the Arizona Biomedical Research Commission and the Michael J. Fox Foundation for Parkinson’s Research. Contributions J.P., P.-C.C., G.Y. M.Z. conceived this project. M.Z., Y.Y, J.Y., A.S.T., R.K., C.R.G., M.T., and S.C. engaged in biophysical experiments. S.Y., Y.H., Z.Wang., H.S., A.H., S.H., Y.J., and P.-C.C. performed biological experiments. P.-C.C., S.M.P.-M., and V.S. generated the Mdk knockout mouse model. S.Y., Z.Wang., L.D., Z.Wu., A.A.H., X.W. contributed to the mass spectrometry-based proteomics analysis. G.E.S. and T.G.B. characterized and provided human brain samples. M.Z., Y.H., P.-C.C. and J.P. wrote the manuscript. Competing interests The authors declare no competing interests. Data availability The mass spectrometry proteomics data were deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifiers PXD046539 (the whole proteome of AD mouse models), and PXD045746 (the aggregated proteome of the mice). Methods All experiments performed in this study comply with all relevant ethical regulations. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at St Jude Children’s Research Hospital. Statistics and reproducibility. Sample sizes were not predetermined using statistical methods; however, they closely resembled those reported in previous publications 68-70 . While the assumption of normal data distribution was made, formal testing for normality was not conducted. Statistical methods were subsequently employed to estimate p-values, and the analysis of false discovery rate was conducted. No exclusions of animals occurred in the study, and the experiments were not randomized. Animals were utilized whenever available without randomization. The investigators were blinded to genotype information during the quantitation of immunostaining for plaque and microglia. Human brain samples . Human postmortem brain tissue samples (frontal gyrus) were provided by the Brain and Body Donation Program at Banner Sun Health Research Institute. Clinical and pathological diagnoses were based on the established criteria 67 . Mouse model. All mice (C57BL/6J) were housed under a 12-h light: 12-h dark cycle at 22-25 °C and 40%-60% humidity. Mdk knockoutmice were generated using CRISPR-Cas9 technology to partially delete coding region in the genome to cause frame shift mutation. Briefly, dual gRNAs were designed with in silico off-target analysis to determine highly unique spacer sequence with at least 3bp of mismatch to any other site in the mouse genome. In addition, we also consider the targeted region covered among all isoforms, and select CAGE257.MDK.g2 (5’- UGCGGCAUGGGCUUCCGCGA- 3’) and g14 (5’-GCACCUUGCAAUGGACGCGC-3’). Precomplexed ribonucleic proteins (RNPs) consisting of 25 ng/µl of each sgRNA (Synthego) and 50 ng/ µl SpCas9 mRNA (Trilink) were injected into the cytoplasm of C57BL/6J fertilized zygotes and transferred to CD-1 psuedopregnant fosters. Resulting animals were genotyped by targeted next generation sequencing using primers CAGE257.F: 5’-GTGAGGCAGGCCGTGTGACCAAGTG-3’ and CAGE257.R:5’- TGCAGTCGGCTGATGGGAGAGTGGC-3’ and analyzed using CRIS.py as previously described 68,69 Founder animals with out-of-frame mutation were backcrossed to C57BL/6J mice for two generations. A founder carrying a 23bp deletion in exon 2 or 3 of all isoforms was selected for the study. FAD mice (B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax) were obtained from Jackson Laboratory (MMRRC_034848-JAX) and underwent backcrossing with C57BL/6J for 10 generations. FAD/Mdk -/- (FAD/KO) mice were generated by crossing with FAD/Mdk +/- with Mdk +/- mice. In all mouse experiments, same ratio of male and female animals was utilized. Western blotting. Protein lysates underwent separation via 4-20% Tris-Glycine gel and transfer to 0.22 µm nitrocellulose membranes. Blots underwent a 1-h blocking with 3% BSA for MDK or 5% skim milk for other targets. The following primary antibodies were incubated overnight at 4°C: anti-mouse MDK (1:1000, sheep polyclonal, R&D, #AF-7769), anti-Aβ (1:1000, mouse monoclonal, clone 82E1, IBL, #10323), and anti-β-tubulin (1:5000, rat monoclonal, clone YOL1/34, abcam, #ab6161). After three 5-minute washes, blots were exposed to secondary antibodies conjugated with HRP (1:40,000, Jackson ImmunoResearch) for 1 h at room temperature, followed by another three 5-minute washes. Chemiluminescence was developed by using either the SuperSignal West Pico PLUS or Femto substrate (Thermo Fisher Scientific) and subsequent detected by ChemiDoc system (Bio-Rad). ELISA analysis. Aβ40 and Aβ42 levels in mouse brain lysate were measured using Meso Scale Diagnostics (MSD) ELISA plate (V-PLEX Aβ Peptide Panel 1 (6E10) Kit) 70 . Briefly, the 96-well plate coated with Aβ40 and Aβ42 antibodies were blocked with blocker diluent for 1 h at room temperature to reduce non-specific protein binding. The plate was washed 3 times with 150 µl /well MSD wash buffer. Then 25 µl of detection antibody followed by 25 µl of diluted standards or mouse brain lysate were loaded and incubated for 2 h. The plate was washed 3 times with 150 µl /well wash buffer. Finally, signals were developed by adding 150 µl of 2x read buffer followed with immediately read on the MESO SECTOR S 600 (MSD). Immunohistochemistry. The staining was modified from previously report 12 . Briefly, brain tissue samples were fixed with 10% formalin buffer, and embedded in paraffin. 5-10 µm sections were deparaffinized, rehydrated and rinsed with water. Antigen retrieval was performed with 10 mM citric buffer (pH 6.0) with boiled water bath for 20 min and cooled down to room temperature. Endogenous peroxidase activity is blocked by 1% H 2 O 2 in PBS buffer for 10 min. After rinsed by PBS, sections were then blocked with 5% donkey serum in PBS with 0.3% Triton X-100 (PBST) for 30 min at room temperature followed with primary antibodies diluted with PBST plus 2% BSA and 0.2% skim milk for overnight at 4°C: anti-human MDK, (goat polyclonal, 1:200, R&D, #AF-258-SP), anti-mouse MDK (1:200, sheep polyclonal, R&D, #AF-7769), anti-Aβ (1:100, clone 82E1, IBL, #10323), anti-IBA1 (1:400, rabbit polyclonal, Fujifilm Wako, #019-19741). After washing with PBS, sections were then incubated with secondary antibodies (1:500, Jackson ImmunoResearch) for 1 hour at room temperature. For immunofluorescence staining of Aβ and IBA1, we used Alexa Fluor 488 and Cy3-conjugated secondary antibodies, respectively. For MDK, we went with HRP polymer-conjugated secondary antibodies (Vector Laboratories, # MP-7405). Signal was amplified using TSA-Cy5 (Akoya Biosciences). For chromogenic immunodetection, biotin-conjugated secondary antibodies were used followed with ABC reaction by Vectastain ABC kit (Vector Laboratories, #PK-4000) and developed by 3,3-diaminobenzidine solution (Vector Laboratories, #SK-4100). Images were captured by Zeiss Axioscan.Z1 and Zeiss LSM 780 confocal microscopy. Quantitation of Aβ plaques and microglia. Brain tissue serially sectioned sagittally at 10 μm thickness. Three slides, each representing every 30th section, were utilized for immunohistochemistry followed with imaging captured with Zeiss Axioscan.Z1. QuPath, an open-source software 71 was carried out for quantitation of density and area of Aβ plaques and microglia in an investigator blinded manner. MDK protein purification. The MDK construct (22-143 aa) was over-expressed in BL21 (DE3) Rosetta 2 cells. A single colony was employed to cultivate a starter culture overnight. Subsequently, 10 ml of the starter culture was utilized to inoculate 1L of 2XYT media, which contained 50 μg/ml Kanamycin and 35 μg/ml Chloramphenicol. The inoculation took place at 37°C, with agitation at 220 rpm, until the cell density reached an OD600 nm of approximately 0.8. The induction of protein over-expression was initiated by adding 0.5 mM Isopropyl β-D-thiogalactopyranoside (IPTG), and the culture was further incubated at 18°C for 16 h. The cells were harvested by centrifugation at 5000 rpm for 15 min at 4 °C and the cell pellet was frozen in - 80°C until used. The cell pellet was resuspended in lysis buffer (20mM HEPES, pH 7.4, 500mM NaCl, 5% glycerol), supplemented with an EDTA-free complete protease inhibitor cocktail tablet (Roche). Disruption was achieved using a cell disruptor (Constant Systems Ltd.) at 20.0 kPSI pressure in 2 rounds of lysis. The resulting lysate was cleared by centrifugation at 20,000 rpm for 30 min at 4 °C and subsequently applied to a gravity column following a 30-minute incubation with pre-equilibrated Ni-NTA resin at 4 °C. The column was then washed by 10 CV of wash buffer A (20mM HEPES pH 7.4, 500mM NaCl, 12.5 mM Imidazole and 5% glycerol), followed by 10 CV of wash buffer B (20mM HEPES pH 7.4, 500mM NaCl, 50 mM Imidazole and 5% glycerol). The protein was eluted with 20mM HEPES pH 7.4, 500mM NaCl, 250 mM Imidazole and 5% glycerol. The eluted fractions were analyzed by loading onto a 4-20% SDS-PAGE gel. Subsequently, the elution fractions were combined, and the His-tag was cleaved from the protein using tobacco etch virus (TEV) protease overnight at 4 °C. The cleaved protein was then further purified by size exclusion chromatography using a Superdex 75 16/600 column (Cytiva) equilibrated with 50 mM Tris-HCl, pH 7.5, 500mM NaCl, and 5% glycerol. Finally, the protein fractions from the column were pooled, concentrated to the desired concentration, flash-frozen in liquid nitrogen, and stored at -80 °C for subsequent experiments. ThT fluorescence assay. Aβ40 and Aβ42 (rPeptide, #A-1153-1, and #A-1163-2) with a purity of > 97%. Each peptide vial was suspended in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), incubated for an hour to disperse any preexisting aggregates. Further these samples were aliquoted and carefully dried in nitrogen stream and stored in -80°C. Aliquots of purified Aβ species were dissolved in 10 mM NaOH to a concentration of 2 mg/ml followed by 10 min cooling and sonication in an ice water bath for 1 min. The concentration of the final monomeric sample was quantified by nanodrop at 280 nm. Purified MDK was dialyzed overnight in 50 mM Tris-HCl buffer, pH 7.5 and final concentration was determined by absorbance measurements at 280 nm Further, the freshly dissolved Aβ peptides were diluted to 5 µM in absence and presence of different concentrations of purified MDK containing 50 mM Tris-HCl, pH 7.5 buffer containing 20 µM Thioflavin. 100 µl of solution was added into 96-well half area, solid bottom, clear, sterile, microtiter plates and sealed with sealing tape to prevent evaporation. All kinetic experiments were performed at 37˚C under quotient conditions at every 5 min in a Clariostar plate reader (BMG Labtech) using an excitation and emission wavelengths of 440 and 480 nm respectively. All these assays were performed in three replicates. Aggregation kinetics of MDK at different concentrations in the same buffer with fixed ThT concentrations were also recorded. NMR HSQC Spectroscopy. The 15 N-labeled Aβ40 and Aβ42 peptides (rPeptide, #A-1101-2 and #A-1102-2) were dissolved in 10mM NaOH to a concentration of 2 mg/ml, followed by 10 min cooling and 1 min sonication in an ice water bath. After aliquoting on ice, the samples were stored in a -80°C freezer. Subsequently, 10 µM of the 15 N-labeled Aβ42 and Aβ40 peptides were incubated with 0, 5, and 10 µM MDK in low-binding tubes (Eppendorf, #0030108434) at 37°C for 24 and 48 h, respectively. The NMR spectra of all these samples including 10 µM monomeric Aβ species were acquired on Bruker Avance 600 MHz or 800 MHz at 278K. The spectrometers are equipped with a triple-resonance cryoprobe, and the data were processed in NMR Pipe 72 . and analyzed using NMRFAM-SPARKY 73 . The backbone resonance assignment of Aβ40 was taken from BMRB (ID: 17795). Binding of MDK to the 15N-labeled Aβ40 and Aβ42 was investigated using two-dimensional (2D) [ 1 H- 15 N] so fast HMQC 74 spectrum recorded either with 32 scans or 128 scans with an interscan delay of 0.2 s. The intensity of the peaks from different spectra were quantified, normalized with respect to the highest peak and used in analyzing the data. Circular dichroism spectroscopy. Aβ aggregated triplicate samples in the absence and presence of MDK were collected directly from the 96-well plates. CD spectra of monomeric and fibrillated Aβ species (in the absence and presence of MDK) were recorded on a JASCO-1500 Spectrophotometer at a wavelength of 195 - 250 nm with a step size of 0.2 nm, 2 nm bandwidth, and a scan speed of 50 nm/min. CD spectra of MDK alone before and after incubation were also recorded. For each sample, the average of five scans was recorded and background correction was done by subtraction of corresponding buffer spectra. Spectra of native and aggregated MDK were collected with the same parameters at a wavelength of 200 to 250 nm. Negative stain transmission electron microscopy. Aβ species alone and reactions involving Aβ together with 10 µM of MDK samples from the kinetic experiments were collected at the end point of the ThT experiments. 400-mesh copper grids (CF400-Cu grids, Electron Microscopy Sciences) were plasma cleaned with an Ar/O2 gas mixture for 10s using Solarus plasma cleaner (Gatan), followed by 5 µl of sample. The samples were allowed to adsorb for 1 min before blotting away the excess liquid, followed by rinsing using Milli Q water and subsequent staining using three successive applications of 2% uranyl acetate. The last round of stain application was allowed to sit for a min before blotting away the excess stain. The grids were air-dried prior to imaging using a 120 kV Talos L120C TEM (Thermo Fisher Scientific) equipped with a CETA detector (TFS). Immunogold negative-stain electron microscopy. Extraction of Aβ filaments was performed as in the previous report 75 . Aβ filaments were deposited on glow-discharged 400 mesh formvar/carbon coated copper grids (EM Sciences CF400-Cu) for 40 s. Subsequently, the grids were blocked for 10 min with 1% BSA in PBS and incubated with anti-MDK (1:50, goat polyclonal, Bio-Techne, #AF-258-SP). After rinsing with blocking buffer, the grids were incubated with anti-goat IgG conjugated with 10 nm gold particle (1:20, Sigma), followed with wash and stained with 2% uranyl acetate for 1 min. Images were acquired at 11,000x with a Gatan Orius SC200B CCD detector on a Tecnai G2 Spirit at 120 kV. Detergent extraction for insoluble proteome. The analysis procedure was adapted from a previously published method 19 . Mouse cortices were extracted with Lysis Buffer (50 mM HEPES, pH 7.5, 5 mM EDTA, 1 mM DTT, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% Sarkosyl, 10% glycerol, and 1x Sigma cOmplete Protease Inhibitor Cocktail). Protein lysates were centrifuged at 3000 x g for 5 min at 4°C. The resulting supernatant was subjected to a second centrifugation at 130,000 x g for 1 h at 4°C. The resulting pellet was washed with 50 mM HEPES containing 0.5% sodium deoxycholate and centrifuged at 17,200 x g for 30 min at 4°C. The insoluble pellet was subsequently resuspended in 8 M Urea with 0.5% sodium deoxycholate for proteome profiling. Mass spectrometry-based proteomics. We used an optimized protocol of TMT-LC/LC-MS/MS for deep proteome profiling 44,45 . Protein samples were lysed by homogenization in the lysis buffer (50 mM HEPES, pH 8.5, 8 M urea, and 0.5% sodium deoxycholate), and their concentrations were measured by the BCA assay (Thermo Fisher Scientific, #23227) and confirmed by Coomassie-stained short SDS gels 76 . Quantified protein samples (~0.1 mg per TMT channel) were digested with Lys-C (1:100 w/w, Wako, distributor, #121-05063) for 2 h at 21 ºC, followed by dilution to decrease urea to 2 M and trypsin digestion (1:50 w/w, Promega, #V5113) overnight at 21 ºC. Cys residues were reduced and alkylated by iodoacetamide. The proteolysis was terminated by adding trifluoroacetic acid to 1%. The resulting peptides were desalted with the Sep-Pak C18 cartridges (Waters), TMT-labeled (Thermo Fisher Scientific, #A34808 and A44520), and pooled equally. The pooled peptides were resolved by basic pH reverse phase LC on an XBridge C18 column (3.5 μm beads, 4.6 mm x 25 cm, Waters; buffer A: 10 mM ammonium formate, pH 8.0; buffer B: 95% acetonitrile, 10 mM ammonium formate, pH 8.0, ~2 h gradient, 40-80 concatenated fractions collected) 77 . Each fraction was analyzed by acidic pH LC-MS/MS (75 µm x ~20 cm, 1.9 µm C18 resin from Dr. Maisch GmbH, buffer A: 0.2% formic acid, 5% DMSO; buffer B: buffer A plus 65% acetonitrile, ~1.5 h gradient). The settings of Q Exactive HF Orbitrap MS (Thermo Fisher Scientific) included the MS1 scan (~410-1600 m/z , 60,000 resolution, 1 x 10 6 AGC and 50 ms maximal ion time) and 20 data-dependent MS2 scans (fixed first mass of 120 m/z , 60,000 resolution, 1 x 10 5 AGC, ~110 ms maximal ion time, HCD, 32-35% normalized collision energy, ~1.0 m/z isolation window with 0.3 m/z offset, and ~15 s dynamic exclusion) 45 . The raw MS data were searched against protein database by the JUMP software (v1.13.4) 78 , which utilizes both pattern matching and de novo tag scoring to improve the sensitivity and specificity. A composite target/decoy database was used to evaluate FDR in peptide identification 79,80 . The protein target database combined downloaded Swiss-Prot, TrEMBL, and UCSC databases (human: 83,955 entries; mouse: 59,423 entries). Search parameters included precursor/product ion mass tolerance (± 10 ppm), full trypticity, static mass shift (TMT tags of 229.16293 and Cys carbamidomethylation of 57.02146 on cysteine), dynamic mass shift (Met oxidation of 15.99491), two maximal miscleavage sites, and three maximal modification sites. Peptide-spectrum matches (PSMs) were filtered by matching scores and mass accuracy to limit protein FDR below 1%. Proteins were quantified from TMT reporter ions based on our published method 46 . Briefly, TMT reporter ion intensities were extracted for each PSM, corrected by isotopic distribution of TMT reagents, filtered to remove poor PSMs (e.g., minimum intensity of 1,000), and adjusted to alleviate sample pooling bias. The relative protein intensities were averaged from all assigned PSMs after removing outliers (e.g., Dixon’s Q-test or generalized extreme Studentized deviate test). Finally, the absolute protein intensities were derived by multiplying the relative intensities by the grand mean of top three abundant PSMs. Pathway enrichment by KEGG and gene ontology databases. Pathway enrichment analysis was carried out by the JUMPn software (v1.13.0) 81 to identify the biological functions of dysregulated genes/proteins in a given dataset. The analysis was performed using Fisher’s exact test against the Gene Ontology (GO) biological process, molecular function, and cellular component annotations, and KEGG pathway database, separately. The homologous genes between human and mouse were used as the background. The p values derived from Fisher’s exact test were further adjusted into FDR using the Benjamini-Hochberg procedure for multiple testing. Enriched pathways with FDR values < 0.05 were considered statistically significant. Protein-protein interaction (PPI) network analysis. The analysis was performed based on our previously published protocol 82 with modifications. DE genes/proteins were superimposed onto a composite PPI database by combining STRING (v11) 83 , BioPlex (v3.0) 84 , and InWeb_IM (v2016_09_12) 85 . The BioPlex database was developed by the method of affinity purification and mass spectrometry, whereas the STRING and InWeb contain information from various sources. Due to this heterogeneity of PPI interactions, the STRING and InWeb databases were further filtered by the edge score to ensure high quality, with the following rules: (i) only edges with evidence of physical interactions (e.g. through co-IP or yeast two-hybrid) were considered; (ii) edges of high confidence, as filtered by the edge score, with the cutoff determined by best fitting the log-log degree distribution using the scale free criteria 86 . The finally accepted STRING and InWeb databases were combined with BioPlex and the inhibitory postsynaptic density interactome 87 to construct a composite PPI database, which includes 20,485 proteins and 1,152,607 PPI connections. PPI modules were then defined by a three-step procedure: (i) extracting a subnetwork by retaining PPI between two proteins if both were from the DE protein list; (ii) calculating a topologically overlapping measure (TOM) 88 between each pair of proteins for the resulting PPI subnetwork, and (iii) dividing this network into individual modules based on the TOM clustering using the hybrid dynamic tree-cutting method 48 . The biological functions of each PPI module were further obtained using the proteins in each module as the input to perform the pathway enrichment analysis as described above. Quantitation and statistical analysis. In small-scale analyses, two-tailed unpaired Student’s t -test was used for two-sample comparisons (Graphpad Prism 7.0.5). Proteomics analysis for differentially expressed proteins primarily utilized the limma R package (v3.48.3) 89 in several steps: (i) obtain the protein quantification data from MS as described above, (ii) perform a log transformation of the data 90 , (iii) calculate the p values by moderated t -test, and FDR values by the Benjamini-Hochberg procedure, using limma R package, (iv) calculate the mean for each protein under different conditions and derive the log2(fold change), (v) fit the log2(fold change) data of all proteins to a Gaussian distribution to generate a 'global' standard deviation value. Statistically significant changes were typically determined using an P value cutoff of 0.05 and a log2 (fold change) cutoff equivalent to two standard deviations. References Alzheimer's_Association. 2023 Alzheimer's disease facts and figures. Alzheimers Dement 19, 1598–1695, doi: 10.1002/alz.13016 (2023). Bellenguez, C., Grenier-Boley, B. & Lambert, J. C. Genetics of Alzheimer's disease: where we are, and where we are going. Curr Opin Neurobiol 61, 40–48, doi: 10.1016/j.conb.2019.11.024 (2020). Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 54, 412–436, doi: 10.1038/s41588-022-01024-z (2022). Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 53, 1276–1282, doi: 10.1038/s41588-021-00921-z (2021). Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002). Ballatore, C., Lee, V. M. & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663–672 (2007). Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006). Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503–1527, doi: 10.1093/brain/awz099 (2019). Bai, B. et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A 110, 16562–16567, doi: 10.1073/pnas.1310249110 (2013). Bai, B. et al. Integrated Approaches for Analyzing U1-70K Cleavage in Alzheimer's Disease. J Proteome Res 13, 4526–4534, doi: 10.1021/pr5003593 (2014). Hales, C. M. et al. U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegener 9, 15, doi: 10.1186/1750-1326-9-15 (2014). Chen, P. C. et al. Alzheimer's disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment. Nat Aging 2, 923–940, doi: 10.1038/s43587-022-00290-0 (2022). Zaman, M. et al. Dissecting Detergent-Insoluble Proteome in Alzheimer's Disease by TMTc-Corrected Quantitative Mass Spectrometry. Mol Cell Proteomics 22, 100608, doi: 10.1016/j.mcpro.2023.100608 (2023). van Dyck, C. H. et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med 388, 9–21, doi: 10.1056/NEJMoa2212948 (2023). Sims, J. R. et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512–527, doi: 10.1001/jama.2023.13239 (2023). Bai, B. et al. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression. Neuron 105, 975–991 (2020). Wang, H. et al. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. Mol Neurodegener 15, 43, doi: 10.1186/s13024-020-00384-6 (2020). Higginbotham, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Sci Adv 6, eaaz9360, doi: 10.1126/sciadv.aaz9360 (2020). Johnson, E. C. B. et al. Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat Neurosci 25, 213–225, doi: 10.1038/s41593-021-00999-y (2022). Sathe, G. et al. Quantitative proteomic analysis of the frontal cortex in Alzheimer's disease. J Neurochem 156, 988–1002, doi: 10.1111/jnc.15116 (2021). Roberts, J. A. et al. A brain proteomic signature of incipient Alzheimer's disease in young APOE epsilon4 carriers identifies novel drug targets. Sci Adv 7, eabi8178, doi: 10.1126/sciadv.abi8178 (2021). Bai, B. et al. Proteomic landscape of Alzheimer's disease: novel insights into pathogenesis and biomarker discovery. Mol Neurodegener 16, 55 (2021). Askenazi, M. et al. Compilation of reported protein changes in the brain in Alzheimer's disease. Nat Commun 14, 4466, doi: 10.1038/s41467-023-40208-x (2023). Liao, L. et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 279, 37061–37068 (2004). Xiong, F., Ge, W. & Ma, C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimers Dement 15, 429–440, doi: 10.1016/j.jalz.2018.10.006 (2019). Drummond, E. et al. The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome. Acta Neuropathol Commun 10, 53, doi: 10.1186/s40478-022-01356-1 (2022). Rahman, M. M. & Lendel, C. Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology. Mol Neurodegener 16, 59, doi: 10.1186/s13024-021-00465-0 (2021). Ross-Munro, E. et al. Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury. Front Neurol 11, 568814, doi: 10.3389/fneur.2020.568814 (2020). Yasuhara, O. et al. Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease. Biochem Biophys Res Commun 192, 246–251, doi: 10.1006/bbrc.1993.1406 (1993). Muramatsu, H. et al. Midkine as a factor to counteract the deposition of amyloid beta-peptide plaques: in vitro analysis and examination in knockout mice. Int Arch Med 4, 1, doi: 10.1186/1755-7682-4-1 (2011). Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129–10140, doi: 10.1523/JNEUROSCI.1202-06.2006 (2006). LeVine, H., 3rd. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2, 404–410, doi: 10.1002/pro.5560020312 (1993). Meisl, G. et al. Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat Protoc 11, 252–272, doi: 10.1038/nprot.2016.010 (2016). Yang, Y. et al. Cryo-EM structures of amyloid-beta 42 filaments from human brains. Science 375, 167–172, doi: 10.1126/science.abm7285 (2022). Kollmer, M. et al. Cryo-EM structure and polymorphism of Abeta amyloid fibrils purified from Alzheimer's brain tissue. Nat Commun 10, 4760, doi: 10.1038/s41467-019-12683-8 (2019). Lu, J. X. et al. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154, 1257–1268, doi: 10.1016/j.cell.2013.08.035 (2013). Sawaya, M. R., Hughes, M. P., Rodriguez, J. A., Riek, R. & Eisenberg, D. S. The expanding amyloid family: Structure, stability, function, and pathogenesis. Cell 184, 4857–4873, doi: 10.1016/j.cell.2021.08.013 (2021). Yang, Y. et al. Cryo-EM structures of amyloid-beta filaments with the Arctic mutation (E22G) from human and mouse brains. Acta Neuropathol 145, 325–333, doi: 10.1007/s00401-022-02533-1 (2023). biorxiv , DOI: 10.1101/2021.1110.1104.463034, doi:10.1101/2021.10.04.463034 (2022). Roche, J., Shen, Y., Lee, J. H., Ying, J. & Bax, A. Monomeric Aβ(1–40) and Aβ(1–42) Peptides in Solution Adopt Very Similar Ramachandran Map Distributions That Closely Resemble Random Coil. Biochemistry 55, 762–775, doi: 10.1021/acs.biochem.5b01259 (2016). Wallin, C. et al. The Neuronal Tau Protein Blocks in Vitro Fibrillation of the Amyloid-β (Aβ) Peptide at the Oligomeric Stage. J Am Chem Soc 140, 8138–8146, doi: 10.1021/jacs.7b13623 (2018). Ito, D. et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57, 1–9, doi: 10.1016/s0169-328x(98)00040-0 (1998). Schwabenland, M. et al. Analyzing microglial phenotypes across neuropathologies: a practical guide. Acta Neuropathol 142, 923–936, doi: 10.1007/s00401-021-02370-8 (2021). Bai, B. et al. Deep Profiling of Proteome and Phosphoproteome by Isobaric Labeling, Extensive Liquid Chromatography, and Mass Spectrometry. Methods Enzymol 585, 377–395 (2017). Wang, Z. et al. 27-plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease. Anal Chem 92, 7162–7170 (2020). Niu, M. et al. Extensive Peptide Fractionation and y1 Ion-Based Interference Detection Method for Enabling Accurate Quantification by Isobaric Labeling and Mass Spectrometry. Anal Chem 89, 2956–2963, doi: 10.1021/acs.analchem.6b04415 (2017). Xie, Y., Pan, W. & Khodursky, A. B. A note on using permutation-based false discovery rate estimates to compare different analysis methods for microarray data. Bioinformatics 21, 4280–4288, doi: 10.1093/bioinformatics/bti685 (2005). Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559, doi: 10.1186/1471-2105-9-559 (2008). Sousa, C. et al. Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures. EMBO Rep 19, doi: 10.15252/embr.201846171 (2018). Zhang, Y. et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37–53, doi: 10.1016/j.neuron.2015.11.013 (2016). Saha, O. et al. The Alzheimer's disease risk gene BIN1 regulates activity-dependent gene expression in human-induced glutamatergic neurons. Molecular psychiatry, doi: 10.1038/s41380-024-02502-y (2024). Voskobiynyk, Y. et al. Alzheimer's disease risk gene BIN1 induces Tau-dependent network hyperexcitability. Elife 9, doi: 10.7554/eLife.57354 (2020). Jaegle, M. et al. The POU factor Oct-6 and Schwann cell differentiation. Science 273, 507–510, doi: 10.1126/science.273.5274.507 (1996). Bermingham, J. R., Jr. et al. Tst-1/Oct-6/SCIP regulates a unique step in peripheral myelination and is required for normal respiration. Genes Dev 10, 1751–1762, doi: 10.1101/gad.10.14.1751 (1996). Stijnen, P., Ramos-Molina, B., O'Rahilly, S. & Creemers, J. W. PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders. Endocr Rev 37, 347–371, doi: 10.1210/er.2015-1117 (2016). Munke, A. et al. Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. Proc Natl Acad Sci U S A 114, 6444–6449, doi: 10.1073/pnas.1700407114 (2017). Månsson, C. et al. Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (Aβ42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. J Biol Chem 289, 31066–31076, doi: 10.1074/jbc.M114.595124 (2014). Cohen, S. I. A. et al. A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat Struct Mol Biol 22, 207–213, doi: 10.1038/nsmb.2971 (2015). Chia, S. et al. Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates. Proc Natl Acad Sci U S A 114, 8005–8010, doi: 10.1073/pnas.1700239114 (2017). Maeda, N. et al. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem 274, 12474–12479, doi: 10.1074/jbc.274.18.12474 (1999). Muramatsu, H. et al. LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 270, 936–941, doi: 10.1006/bbrc.2000.2549 (2000). Muramatsu, H. et al. alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 117, 5405–5415, doi: 10.1242/jcs.01423 (2004). Ichihara-Tanaka, K., Oohira, A., Rumsby, M. & Muramatsu, T. Neuroglycan C is a novel midkine receptor involved in process elongation of oligodendroglial precursor-like cells. J Biol Chem 281, 30857–30864, doi: 10.1074/jbc.M602228200 (2006). Stoica, G. E. et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277, 35990–35998, doi: 10.1074/jbc.M205749200 (2002). Huang, Y. et al. Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle 7, 1613–1622, doi: 10.4161/cc.7.11.5952 (2008). Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15, 501–518, doi: 10.1038/s41582-019-0228-7 (2019). Beach, T. G. et al. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 35, 354–389, doi: 10.1111/neup.12189 (2015). Connelly, J. P. & Pruett-Miller, S. M. CRIS.py: A Versatile and High-throughput Analysis Program for CRISPR-based Genome Editing. Sci Rep 9, 4194, doi: 10.1038/s41598-019-40896-w (2019). Narina, S., Connelly, J. P. & Pruett-Miller, S. M. High-Throughput Analysis of CRISPR-Cas9 Editing Outcomes in Cell and Animal Models Using CRIS.py. Methods Mol Biol 2631, 155–182, doi: 10.1007/978-1-0716-2990-1_6 (2023). Petit, D. et al. Aβ profiles generated by Alzheimer’s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular psychiatry 27, 2821–2832, doi: 10.1038/s41380-022-01518-6 (2022). Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci Rep 7, 16878, doi: 10.1038/s41598-017-17204-5 (2017). Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6, 277–293, doi: 10.1007/bf00197809 (1995). Lee, W., Tonelli, M. & Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 31, 1325–1327, doi: 10.1093/bioinformatics/btu830 (2015). Schanda, P., Kupce, E. & Brutscher, B. SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR 33, 199–211, doi: 10.1007/s10858-005-4425-x (2005). Yang, Y. et al. Cryo-EM structures of amyloid-β 42 filaments from human brains. Science 375, 167–172, doi: 10.1126/science.abm7285 (2022). Xu, P., Duong, D. M. & Peng, J. Systematical Optimization of Reverse-Phase Chromatography for Shotgun Proteomics. J Proteome Res 8, 3944–3950, doi: 10.1021/pr900251d (2009). Wang, H. et al. Systematic optimization of long gradient chromatography mass spectrometry for deep analysis of brain proteome. J Proteome Res 14, 829–838, doi: 10.1021/pr500882h (2015). Wang, X. et al. JUMP: a tag-based database search tool for peptide identification with high sensitivity and accuracy. Mol Cell Proteomics 13, 3663–3673, doi: 10.1074/mcp.O114.039586 (2014). Peng, J., Elias, J. E., Thoreen, C. C., Licklider, L. J. & Gygi, S. P. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res 2, 43–50 (2003). Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4, 207–214 (2007). Vanderwall, D. et al. JUMPn: A Streamlined Application for Protein Co-Expression Clustering and Network Analysis in Proteomics. J Vis Exp 176, 10.3791/62796, doi: 10.3791/62796 (2021). Tan, H. et al. Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation. Immunity 46, 488–503, doi: 10.1016/j.immuni.2017.02.010 (2017). Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, D447-452, doi: 10.1093/nar/gku1003 (2015). Huttlin, E. L. et al. The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 162, 425–440, doi: 10.1016/j.cell.2015.06.043 (2015). Li, T. et al. A scored human protein-protein interaction network to catalyze genomic interpretation. Nat Methods 14, 61–64, doi: 10.1038/nmeth.4083 (2017). Barabasi, A. L. & Oltvai, Z. N. Network biology: understanding the cell's functional organization. Nat Rev Genet 5, 101–113, doi: 10.1038/nrg1272 (2004). Uezu, A. et al. Identification of an elaborate complex mediating postsynaptic inhibition. Science 353, 1123–1129, doi: 10.1126/science.aag0821 (2016). Ravasz, E., Somera, A. L., Mongru, D. A., Oltvai, Z. N. & Barabasi, A. L. Hierarchical organization of modularity in metabolic networks. Science 297, 1551–1555, doi: 10.1126/science.1073374 (2002). Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47, doi: 10.1093/nar/gkv007 (2015). Mertens, B. J. A. Transformation, Normalization, and Batch Effect in the Analysis of Mass Spectrometry Data for Omics Studies. Statistical Analysis of Proteomics, Metabolomics, and Lipidomics Data Using Mass Spectrometry , 1–21 (2016). Additional Declarations There is NO Competing Interest. Supplementary Files MDKExtendedDataTablesv1.0.0.xlsx ExtendedDataFig.docx Cite Share Download PDF Status: Published Journal Publication published 21 Aug, 2025 Read the published version in Nature Structural & Molecular Biology → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4361125","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":303322328,"identity":"b69347bc-43ad-4dbd-abad-dc27734efaca","order_by":0,"name":"Junmin Peng","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA+ElEQVRIiWNgGAWjYBACxgYgkQBlP2BgYGNgOECCFmYDhgQitCADNgmwZkJamGfkHt3wcAdDHr90+7XKnz/4EvuONzA+rviFx2Ez8tJuJJ5hKJacc6bsNk8CW+LMMweYDc/24dOSY3YjsY0hccONnLTbQL8AGQlsko09RGjZD9RS+AOk5f4DIrVskEg/xsADtoWBTbLhBx4tPW9AWiSKJW7kMEvzpLEZzzyT2GzY2IBbi2F7jtnNn202efwz0h9+/GFzTLbv+OGDDxv+4NECMU4igYGBxwDIOMYAjl7GNtxa5KE0UAv7AyBdA+XjsWUUjIJRMApGHAAATA1bvc6DxGoAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0003-0472-7648","institution":"St Jude Children's Research Hospital","correspondingAuthor":true,"prefix":"","firstName":"Junmin","middleName":"","lastName":"Peng","suffix":""},{"id":303322329,"identity":"952f4342-635d-4904-9108-60fa5a278978","order_by":1,"name":"Masihuz Zaman","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Masihuz","middleName":"","lastName":"Zaman","suffix":""},{"id":303322330,"identity":"a3c2536f-70c8-40ff-ac6c-49e9d345301d","order_by":2,"name":"Shu Yang","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Shu","middleName":"","lastName":"Yang","suffix":""},{"id":303322331,"identity":"f985e932-8883-44fb-bf1a-a96b5a51668a","order_by":3,"name":"Ya Huang","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ya","middleName":"","lastName":"Huang","suffix":""},{"id":303322332,"identity":"cf2d9c39-820c-4415-a229-1b405e00c9aa","order_by":4,"name":"Jay Yarbro","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Jay","middleName":"","lastName":"Yarbro","suffix":""},{"id":303322333,"identity":"793525ac-cf23-4d05-8159-c357559b5cfc","order_by":5,"name":"Zhen Wang","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Zhen","middleName":"","lastName":"Wang","suffix":""},{"id":303322334,"identity":"e971fa60-9cfa-44dc-807e-99c9f9ae7564","order_by":6,"name":"Danting Liu","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Danting","middleName":"","lastName":"Liu","suffix":""},{"id":303322335,"identity":"e93145d8-acb4-484f-b54c-b95958d0e643","order_by":7,"name":"Hadeer Soliman","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hadeer","middleName":"","lastName":"Soliman","suffix":""},{"id":303322336,"identity":"8ced0830-9aa9-4396-ba03-929e184d48f6","order_by":8,"name":"Alex Hemphill","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Alex","middleName":"","lastName":"Hemphill","suffix":""},{"id":303322337,"identity":"73e4bdef-4063-4c4d-908f-d6382574bfbe","order_by":9,"name":"Sarah Harvey","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Sarah","middleName":"","lastName":"Harvey","suffix":""},{"id":303322338,"identity":"26bfdbe7-37f1-4c3f-b582-f99c7666dc82","order_by":10,"name":"Shondra Pruett-Miller","email":"","orcid":"https://orcid.org/0000-0002-3793-585X","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Shondra","middleName":"","lastName":"Pruett-Miller","suffix":""},{"id":303322339,"identity":"be04a327-70c7-40e7-8d56-580a00935dac","order_by":11,"name":"Valerie Stewart","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Valerie","middleName":"","lastName":"Stewart","suffix":""},{"id":303322340,"identity":"5bc9b6c2-e0cd-489f-b4ad-95d867c76a80","order_by":12,"name":"Ajay Tanwar","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ajay","middleName":"","lastName":"Tanwar","suffix":""},{"id":303322341,"identity":"f398e6b7-6701-426b-82b1-f0bcfe8867be","order_by":13,"name":"Ravi Kalathur","email":"","orcid":"https://orcid.org/0000-0002-4889-8003","institution":"St. Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ravi","middleName":"","lastName":"Kalathur","suffix":""},{"id":303322342,"identity":"fc682c77-e089-4798-b106-9def1594331f","order_by":14,"name":"Christy Grace","email":"","orcid":"https://orcid.org/0000-0002-1600-5610","institution":"St. Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Christy","middleName":"","lastName":"Grace","suffix":""},{"id":303322343,"identity":"c86a0af1-9d66-4a40-9df0-46f59a7cff5b","order_by":15,"name":"Martin Turk","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Martin","middleName":"","lastName":"Turk","suffix":""},{"id":303322344,"identity":"0c8c4dd6-aab2-4d87-8b1e-cd95de83d912","order_by":16,"name":"Sagar Chittori","email":"","orcid":"https://orcid.org/0000-0003-1417-6552","institution":"St. Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Sagar","middleName":"","lastName":"Chittori","suffix":""},{"id":303322345,"identity":"31b20168-9c86-4d07-9906-c4d7fcb33657","order_by":17,"name":"Yun Jiao","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yun","middleName":"","lastName":"Jiao","suffix":""},{"id":303322346,"identity":"d79a114d-ca7c-4d46-a919-d5b792280499","order_by":18,"name":"Zhiping Wu","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Zhiping","middleName":"","lastName":"Wu","suffix":""},{"id":303322347,"identity":"89e2e65f-df89-40ee-9fd1-513cd2715d70","order_by":19,"name":"Anthony High","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Anthony","middleName":"","lastName":"High","suffix":""},{"id":303322348,"identity":"b51babbd-e4ab-4393-bcd2-17372f6dd710","order_by":20,"name":"Xusheng Wang","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xusheng","middleName":"","lastName":"Wang","suffix":""},{"id":303322349,"identity":"3f7a63ed-5bbe-465a-aecd-2e9810d45665","order_by":21,"name":"Geidy Serrano","email":"","orcid":"","institution":"Banner Sun Health Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Geidy","middleName":"","lastName":"Serrano","suffix":""},{"id":303322350,"identity":"9f207849-21b4-4002-832a-820761f36db2","order_by":22,"name":"Thomas Beach","email":"","orcid":"","institution":"Banner Sun Health Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Thomas","middleName":"","lastName":"Beach","suffix":""},{"id":303322351,"identity":"f71176db-56a7-46a0-b676-62145dfacce4","order_by":23,"name":"Gang Yu","email":"","orcid":"https://orcid.org/0000-0003-4932-5757","institution":"University of Texas Southwestern Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Gang","middleName":"","lastName":"Yu","suffix":""},{"id":303322352,"identity":"4ad1c5a7-3204-4d99-bd24-a6a8652ac9f4","order_by":24,"name":"Yang Yang","email":"","orcid":"","institution":"Van Andel Institute,","correspondingAuthor":false,"prefix":"","firstName":"Yang","middleName":"","lastName":"Yang","suffix":""},{"id":303322353,"identity":"864907bb-9cdb-4543-a139-b354131ea13f","order_by":25,"name":"Ping-Chung Chen","email":"","orcid":"","institution":"St Jude Children's Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ping-Chung","middleName":"","lastName":"Chen","suffix":""}],"badges":[],"createdAt":"2024-05-02 22:15:17","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4361125/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4361125/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41594-025-01657-8","type":"published","date":"2025-08-21T04:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":57936842,"identity":"78973521-ab86-41d2-bb04-3b214eeb8b61","added_by":"auto","created_at":"2024-06-07 17:30:50","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":4719626,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMDK is an Aβ-correlated protein in AD, and it inhibits the fibril assembly of Aβ40 and Aβ42 peptides.\u003c/strong\u003e \u003cstrong\u003ea\u003c/strong\u003e, Pearson correlation analysis on MDK in relation to tau or Aβ levels using human brain proteomic datasets (111 cases)\u003csup\u003e16\u003c/sup\u003e. Protein levels were standardized to z scores. \u003cstrong\u003eb\u003c/strong\u003e, IHC staining of MDK in both control and AD brain tissues, with the scale bar shown. \u003cstrong\u003ec\u003c/strong\u003e, Co-immunofluorescence staining of Aβ and MDK in AD brain, with the scale bar shown. \u003cstrong\u003ed\u003c/strong\u003e, The ThT fluorescence assay to detect Aβ40 amyloid fibril formation, with titrated MDK protein (\u003cem\u003en\u003c/em\u003e = 3 replicates, averaged data presented). \u003cstrong\u003ee\u003c/strong\u003e, Analysis of secondary nucleation rate constant (\u003cem\u003ek\u003c/em\u003e\u003csub\u003e2\u003c/sub\u003e) by globally fitting the ThT data using AmyloFit software\u003csup\u003e33\u003c/sup\u003e, estimating the rate constant of \u003cem\u003ek\u003c/em\u003e\u003csub\u003e2\u003c/sub\u003e at each MDK concentration in a unit (M \u003csup\u003e-2 \u003c/sup\u003eh \u003csup\u003e-1\u003c/sup\u003e), followed by log transformation and linear fitting of these values at different MDK concentrations. \u003cstrong\u003ef\u003c/strong\u003e, CD spectroscopy of the samples of Aβ40 mixed with or without MDK, with ellipticity reported in millidegrees (mdeg). \u003cstrong\u003eg\u003c/strong\u003e, The ThT assay of Aβ42 and MDK (\u003cem\u003en\u003c/em\u003e = 3 replicates, averaged data shown). \u003cstrong\u003eh\u003c/strong\u003e, Analysis of secondary nucleation rate constant of \u003cem\u003ek\u003c/em\u003e\u003csub\u003e2\u003c/sub\u003e by AmyloFit. The data points under the condition of 10 µM MDK did not globally fit well with the AmyloFit model, were therefore removed from the fitting. \u003cstrong\u003ei\u003c/strong\u003e, CD spectroscopy of the Aβ42/MDK samples.\u003cstrong\u003e j-k\u003c/strong\u003e, Negative stain EM of Aβ40/MDK and Aβ42/MDK samples, respectively, with the scale bars shown.\u003cbr\u003e\n\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4361125/v1/80f6515d4f37b73072bec99b.png"},{"id":57936841,"identity":"02378dca-d7da-45f4-bc60-7a746743b3a8","added_by":"auto","created_at":"2024-06-07 17:30:50","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":617022,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMDK rescues NMR signals of Aβ peptides. a, \u003c/strong\u003e\u003csup\u003e1\u003c/sup\u003eH-\u003csup\u003e15\u003c/sup\u003eN HSQC spectra of Aβ40 (10 μM) with MDK concentrations of 0, 5, or 10 μM in a buffer containing of 50 mM Tris buffer, pH 7.5. The spectra were collected prior to incubation (the left panel) and after 48 h incubation (the right three panels). \u003cstrong\u003eb,\u003c/strong\u003e Relative cross peak intensities for each residue, excluding D1 and H14. The intensities were normalized with the maximum intensity set to 1. \u003cstrong\u003ec,\u003c/strong\u003e Relative percentage of Aβ40 intensities after 48 h incubation compared to those before incubation. The percentage values were calculated for each residue and then averaged to show the mean and standard error of the mean (SEM). Statistical significance is analyzed by two-tailed Student's \u003cem\u003et\u003c/em\u003e-test. \u003cstrong\u003ed-f, \u003c/strong\u003eThe HSQC spectra of Aβ42 under similar conditions as Aβ40, but with the incubation time shortened to 24 h. Statistical significance is analyzed by two-tailed Student's \u003cem\u003et\u003c/em\u003e-test.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-4361125/v1/e85720e9927647a51bf3f434.png"},{"id":57936846,"identity":"d4100828-0768-462a-af6b-de46da88ce53","added_by":"auto","created_at":"2024-06-07 17:30:50","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":3619836,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eMdk\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e gene knockout in FAD results in Aβ accumulation, plaque increase and microglia activation. a\u003c/strong\u003e, The diagram of the \u003cem\u003eMdk\u003c/em\u003e gene structure, which comprises five exons, including the first exon as the 5’ untranslated region. We targeted a CRISPR-mediated deletion of a specific DNA segment within exon 3, resulting in a gene knockout that disrupts the open reading frame sequence. Crossbreeding of the \u003cem\u003eMdk \u003c/em\u003eKO with FAD resulted in the generation of four genotypes for comparisons. \u003cstrong\u003eb\u003c/strong\u003e, PCR genotyping of the WT and homogenous \u003cem\u003eMdk\u003c/em\u003e KO. \u003cstrong\u003ec\u003c/strong\u003e, Western blotting to confirm the loss of MDK protein and the increase of Aβ in the brain of heterogenous FAD mice with homogenous \u003cem\u003eMdk \u003c/em\u003eKO (12-month-old,\u003cem\u003e n\u003c/em\u003e = 3 replicates). \u003cstrong\u003ed\u003c/strong\u003e, Aβ ELISA analysis (\u003cem\u003en\u003c/em\u003e = 4 replicates). \u003cstrong\u003ee\u003c/strong\u003e, Quantification of amyloid plaque density and area (\u003cem\u003en\u003c/em\u003e = 4 replicates). \u003cstrong\u003ef\u003c/strong\u003e. Quantification of microglia density and area (\u003cem\u003en\u003c/em\u003e = 4 replicates). \u003cstrong\u003eg\u003c/strong\u003e. Co-immunofluorescence staining of Aβ, MDK and IBA1 in the mouse brains. Scale bar, 50 µm. Statistical significance is analyzed by two-tailed Student's \u003cem\u003et\u003c/em\u003e-test.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-4361125/v1/b6544cc449e5069d18846f26.png"},{"id":57937463,"identity":"04d3db03-5792-4863-b9cc-30cc7ff83798","added_by":"auto","created_at":"2024-06-07 17:38:50","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":503775,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eBrain tissue proteomics reveals \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eMdk\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e knockout causes the accumulation of Aβ and Aβ-correlated proteins, along with microglia activation in FAD.\u003c/strong\u003e \u003cstrong\u003ea\u003c/strong\u003e, Workflow of whole proteome analysis of the brain cortical region for four mouse genotypes (12-month-old, \u003cem\u003en\u003c/em\u003e = 4 replicates for each genotype). \u003cstrong\u003eb\u003c/strong\u003e, Clustering of the whole proteome to show the grouping of four genotypes using DEPs. \u003cstrong\u003ec\u003c/strong\u003e, MDK and Aβ levels extracted from the whole proteome analysis. \u003cstrong\u003ed\u003c/strong\u003e, Four major clusters of DEPs defined by the WGCNA program. The intensity of each protein is log transformed followed by Z score analysis. \u003cstrong\u003ee\u003c/strong\u003e, Enriched pathways in the WPC proteins by Fisher’s exact test. \u003cstrong\u003ef\u003c/strong\u003e, Workflow of profiling the aggregated proteome in FAD and FAD/KO mice (12-month-old, \u003cem\u003en\u003c/em\u003e = 4 replicates). \u003cstrong\u003eg\u003c/strong\u003e, Heatmap for selected proteins shared by the whole proteome and aggregated proteome. The data are shown after normalization by z score transformation. \u003cstrong\u003eh\u003c/strong\u003e, Ntn1 and Ptn protein levels selected from the whole and aggregated proteome analyses. Statistical significance is determined by a two-tailed Student's \u003cem\u003et\u003c/em\u003e-test, and the results are shown as mean ± SEM. *: P \u0026lt; 0.05; **: P \u0026lt; 0.01; and ***: P \u0026lt; 0.001.\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-4361125/v1/93b880adf55b2c50070d031f.png"},{"id":89717249,"identity":"5b5a6554-ff05-4b43-bf66-fb27483ae15c","added_by":"auto","created_at":"2025-08-23 07:13:13","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":11917971,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4361125/v1/a6a8b523-6dda-4d23-a2c6-6f886af3de3c.pdf"},{"id":57936845,"identity":"3bd3398f-7e40-4728-8f5d-d7b9a39d51de","added_by":"auto","created_at":"2024-06-07 17:30:50","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":5558665,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"MDKExtendedDataTablesv1.0.0.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4361125/v1/1c089c4e454e4754e3204e9b.xlsx"},{"id":57936844,"identity":"9d8ab3b0-740b-43c7-b330-fab060d22ffc","added_by":"auto","created_at":"2024-06-07 17:30:50","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":13119725,"visible":true,"origin":"","legend":"","description":"","filename":"ExtendedDataFig.docx","url":"https://assets-eu.researchsquare.com/files/rs-4361125/v1/471cc82894ec12c7a8c2cff9.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"Midkine Attenuates Aβ Fibril Assembly and Amyloid Plaque Formation","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAlzheimer's disease (AD), an irreversible and progressive neurodegenerative disorder, is the primary cause of dementia\u003csup\u003e1\u003c/sup\u003e.\u0026nbsp;Genetic studies have revealed disease-specific genes (APP, PS1, PS2), high-risk genes (APOE4, TREM2, UNC5C), and\u0026nbsp;a large number of risk loci associated with amyloid, tau, endocytosis, and immunity\u003csup\u003e2-4\u003c/sup\u003e. The dysregulation in the AD proteome within the brain is characterized by the accumulation of Aβ amyloid plaques\u003csup\u003e5\u003c/sup\u003e, tau neurofibrillary tangles\u003csup\u003e6\u003c/sup\u003e, and other aggregated proteins, including TDP-43\u003csup\u003e7,8\u003c/sup\u003e and U1 snRNP\u003csup\u003e9-13\u003c/sup\u003e.\u0026nbsp;The recent FDA approval of lecanemab\u003csup\u003e14\u003c/sup\u003e, along with the promising Phase III trial results for Donanemab\u003csup\u003e15\u003c/sup\u003e, both being amyloid-targeting antibodies, lend support to the amyloid cascade hypothesis. However, the limited clinical benefits for AD patients suggest the presence of alternative disease mechanisms and imply that intervention at a late disease stage may be insufficient.\u003c/p\u003e\n\u003cp\u003eComplementary to the genetic search for AD disease genes, we and others have performed large-scale proteomic profiling, uncovering consistent protein alterations in post-mortem AD brains across multiple large cohorts from various independent research groups\u003csup\u003e16-23\u003c/sup\u003e. This has highlighted the deregulation of numerous molecular pathways and protein co-expression modules. Remarkably, a subgroup of proteins is highly upregulated and show a strong correlation with Aβ levels since the early prodromal stage throughout disease progression, including\u0026nbsp;midkine (MDK), pleiotrophin (PTN), netrin 1 (NTN1), netrin 3 (NTN3) and the HTRA1 serine protease\u003csup\u003e16,19\u003c/sup\u003e.\u0026nbsp;Interestingly, these protein changes occur independently of their mRNA transcript levels, indicating post-transcriptional regulation\u003csup\u003e16,19\u003c/sup\u003e. Moreover, these Aβ-correlated proteins have been found in the detergent-insoluble, aggregated proteome, and within amyloid plaques in AD brains, as confirmed by mass spectrometry-based profiling and immunohistochemical analyses\u003csup\u003e13,24-27\u003c/sup\u003e.\u0026nbsp;However, the direct involvement of these Aβ-correlated proteins in plaque formation and AD pathogenesis remains to be elucidated.\u003c/p\u003e\n\u003cp\u003eThe MDK/PTN family of cytokines, consisting of only two members\u003csup\u003e28\u003c/sup\u003e, are among the most closely Aβ-correlated proteins identified in proteomic analyses\u003csup\u003e16,19\u003c/sup\u003e. They are multifunctional heparin-binding factors that promote growth, survival, and migration of various cell types, including neurons and immune cells\u003csup\u003e28\u003c/sup\u003e. In 1993, MDK was reported to localize within the amyloid plaques associated with AD\u003csup\u003e29\u003c/sup\u003e. Preliminary studies suggest that MDK might directly interact with Aβ, displaying high affinity and potentially mitigating Aβ's toxic effects\u003csup\u003e30\u003c/sup\u003e, but the study had not received attention in the AD research field. Recent proteomic findings support MDK as a top candidate for modulating AD pathogenesis\u003csup\u003e16,19\u003c/sup\u003e, raising interest in fully exploring the role of MDK in AD.\u003c/p\u003e\n\u003cp\u003eIn this study, we have thoroughly characterized the impact of MDK on Aβ assembly in various assays including Thioflavin T, circular dichroism, negative stain electron microscopy (EM), and NMR, demonstrating that MDK protein inhibits the formation of Aβ fibrils. Importantly, the \u003cem\u003eMdk\u003c/em\u003e gene knockout (KO) in the background of 5xFAD mice leads to the amyloid increase and microglial activation. Further proteomic profiling of these mouse models reveals the accumulated Aβ and related proteins in the brain of the 5xFAD/KO mice, supporting MDK's protective role against amyloid pathology in AD.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec2\" class=\"Section2\"\u003e \u003ch2\u003eMDK, a top Aβ-correlated protein in human brain, attenuates Aβ fibril assembly\u003c/h2\u003e \u003cp\u003eAlthough MDK was identified within the senile plaques of AD patients by antibodies last century\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e, its role in AD has not been well investigated. Recent unbiased proteomic analyses have highlighted MDK as one of the top upregulated proteins highly correlated with Aβ\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. To verify these findings, we re-analyzed an AD proteomic dataset comprising 111 human cases\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e, and performed Pearson correlation analyses of all identified proteins with Aβ and tau levels (\u003cb\u003eExtended Data Table\u0026nbsp;1\u003c/b\u003e). Strikingly, among more than 8,400 identified proteins, MDK shows the best correlation with Aβ levels (R\u0026thinsp;=\u0026thinsp;0.90) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ea). In contrast, MDK displays a much weaker correlation with tau (R\u0026thinsp;=\u0026thinsp;0.29), consistent with the idea that Aβ and tau do not strongly correlate during the progression of AD (R\u0026thinsp;=\u0026thinsp;0.26). The presence of MDK in the plaque regions of the human brain was further confirmed through immunohistochemical (IHC) staining and immunofluorescent co-staining with Aβ peptides (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eb, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ec). Additionally, in the 5xFAD amyloidosis mouse model (also termed FAD for simplicity), which overexpresses mutant human APP and PSEN1 genes\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e, MDK accumulation was observed to be higher in FAD mice than in wild type (WT), corroborated by antibody-based detection of MDK in mouse plaques (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ea, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eb, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ec). These findings not only reaffirm the strong Aβ-MDK correlation in human but also suggest the FAD mice as a valuable model for studying the role of MDK in AD pathogenesis.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eGiven the previous reports that MDK protein directly binds to Aβ peptides\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e, we investigated its impact on Aβ fibrillization using various biophysical assays. Highly purified recombinant human MDK protein (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ed) at concentrations ranging from 1 \u0026micro;M to 10 \u0026micro;M, was incubated with synthetic Aβ40 peptide at 5 \u0026micro;M. The fibrillization process was monitored by the fluorescence of thioflavin T (ThT), in which the fluorescence intensity increases upon binding with amyloid fibrils\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. As anticipated, in the absence of MDK, Aβ40 displayed a time-dependent increase in fibrillization, with increased lag time and decreased ThT fluorescence intensity in a dose-dependent manner (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ed). We further turned to the AmyloFit software\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e to determine effects of MDK on the microscopic steps during the aggregation of Aβ. The best fit revealed that MDK negatively impacts Aβ40 secondary nucleation rate constant (\u003cem\u003ek\u003c/em\u003e\u003csub\u003e2\u003c/sub\u003e) and elongation constant (\u003cem\u003ek\u003c/em\u003e\u003csub\u003e+\u003c/sub\u003e), as both log\u003csub\u003e2\u003c/sub\u003e(\u003cem\u003ek\u003c/em\u003e\u003csub\u003e2\u003c/sub\u003e) and log\u003csub\u003e2\u003c/sub\u003e(\u003cem\u003ek\u003c/em\u003e\u003csub\u003e+\u003c/sub\u003e) values show a linear decrease with increasing MDK concentrations (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ee, \u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ee, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ef). Following a 24 h incubation, far UV circular dichroism (CD) analysis of the Aβ40 samples confirmed the inhibitory effect of MDK on Aβ40 fibrillization. Aβ40 in absence of MDK initiated from unstructured random coil confirmation (0 h) to β-sheet structure (24 h). However, in the presence of MDK (10 \u0026micro;M) Aβ40 essentially retained into the unstructured confirmation like monomers (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ef). We extended this study to synthetic Aβ42 peptide, yielding similar outcomes (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eg, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eh, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ei, \u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eg). Moreover, the Aβ40/Aβ42 samples, with and without MDK, were examined using negative stain EM analysis (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ej, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ek). Amyloid fibrils were observed as the end-point aggregates of samples of Aβ40/Aβ42 peptide (5 \u0026micro;M) alone. In contrast, the presence of high concentration of MDK (10 \u0026micro;M, 2:1 molar ratio) produced some nonfibrillar aggregates, demonstrating MDK's potential to inhibit Aβ fibril formation effectively. It is important to note that MDK alone does not fibrillate under similar conditions as confirmed by ThT binding assay, far UV CD, and negative stain results (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eh, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ei, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ej). Together, these results suggest that midkine is inhibiting the formation of amyloid fibrils \u003cem\u003ein vitro\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eIn spite of the inhibition effect of MDK on Aβ assembly, we observed that Aβ could still assemble as fibrils in the presence of lower MDK concentrations, such as a 1:1 molar ratio, and subsequently examined the Aβ42 fibrils under this condition using negative stain and immunogold electron microscopy. Although the resolution was low, the Aβ42 fibrils appeared to be surrounded by protein molecules (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea). As recombinant Aβ fibrils assemble differently from endogenous Aβ filaments found in human brains\u003csup\u003e\u003cspan additionalcitationids=\"CR35 CR36 CR37\" citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e, we further investigated the presence of MDK in Aβ fibrils extracted from human AD brains. Immunogold negative stain EM with the MDK antibodies revealed that MDK molecules are clustered around these Aβ fibrils (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb). Moreover, we utilized the AlphaFold2-multimer prediction tool\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e to hypothesize possible Aβ-MDK interacting interfaces, suggesting that the N-terminus of Aβ (residues 1\u0026ndash;12) might interact with the C-terminus of MDK (residues 74\u0026ndash;80 and 84\u0026ndash;89) (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ec, \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ed).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTo further confirm the effect of MDK on Aβ fibrillization, we acquired \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003eH-\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003eN HSQC NMR spectra of \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003eN-labeled monomeric Aβ40 (10 \u0026micro;M) with MDK titration (0, 5, and 10 \u0026micro;M, Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea). Reference spectra were acquired prior to incubation, with amide cross peaks assigned to specific residues\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. After 48 h, a notable disappearance of cross peaks suggested Aβ40 peptide fibrillization. Remarkably, with MDK co-incubation at varying concentrations, the cross peaks re-appeared although at reduced intensities. As the HSQC cross peak intensities correlate with monomeric Aβ concentration\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e, we quantified the cross peak intensities for each residue (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb), and calculated the averaged percentage relative to the pre-incubation reference of Aβ40. The MDK addition (5 \u0026micro;M and 10 \u0026micro;M) rescued the cross peak intensities from 0.9\u0026thinsp;\u0026plusmn;\u0026thinsp;0.2% to 38.3\u0026thinsp;\u0026plusmn;\u0026thinsp;1.1% and 38.1\u0026thinsp;\u0026plusmn;\u0026thinsp;0.9%, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ec). We also observed a similar impact of MDK on Aβ42 fibrillization using a protocol of 24 h incubation (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ed). However, the same concentrations of MDK were less effective in recovering Aβ42 cross peaks compared to Aβ40 (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ee, \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ef). For example, the MDK addition (5 \u0026micro;M and 10 \u0026micro;M) retrieved the cross peak intensities from 4.8\u0026thinsp;\u0026plusmn;\u0026thinsp;0.5% to 12.8\u0026thinsp;\u0026plusmn;\u0026thinsp;0.8% and 21.8\u0026thinsp;\u0026plusmn;\u0026thinsp;0.8%, respectively. This aligns with our ThT, CD and negative stain EM data, supporting the notion that Aβ42 is more aggregation prone than Aβ40\u003csup\u003e37\u003c/sup\u003e. In summary, our comprehensive biophysical characterization strongly demonstrates that MDK can modulate Aβ fibrillization in vitro.\u003c/p\u003e \u003cp\u003e \u003cb\u003eGenetic deletion of\u003c/b\u003e \u003cb\u003eMdk\u003c/b\u003e \u003cb\u003egene in FAD mice increases amyloid plaques and microglial activation.\u003c/b\u003e\u003c/p\u003e \u003cp\u003eTo investigate the role of MDK in Aβ fibrillization in vivo, we generated a mouse model with an \u003cem\u003eMdk\u003c/em\u003e gene knockout by CRISPR-mediated deletion of 23 base pairs in exon 3 of the mouse genome (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ea). The deletion was confirmed through genome sequencing and PCR analysis (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eb), with the absence of MDK protein verified by western blot analysis (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ec). We crossbred this knockout line with the FAD mice to produce offspring that were either FAD mice with or without the \u003cem\u003eMdk\u003c/em\u003e knockout. The \u003cem\u003eMdk\u003c/em\u003e knockout resulted in a marked increase in Aβ levels in the cortex of 12-month-old mice brains, as shown by western blot analysis (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ec). Further, ELISA analysis indicated elevated accumulation of both Aβ40 and Aβ42 peptides in the brain lysate (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ed). These biochemical findings indicate that \u003cem\u003eMdk\u003c/em\u003e gene knockout contributes to the increased accumulation of two major Aβ species in the FAD genetic background.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eNext, we characterized the FAD/KO mice through immunostaining to evaluate the effects of \u003cem\u003eMdk\u003c/em\u003e deletion on plaque formation and microglial activation in the brain. As anticipated, \u003cem\u003eMdk\u003c/em\u003e knockout resulted in increased plaque density and area in the cortex of 12-month-old mouse brains (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ee), which was accompanied by heightened microglial activation, evidenced by the rise in microglia density and area (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ef). In subsequent immunofluorescence staining studies, amyloid plaques detected by the Aβ antibody were found to highly colocalize with MDK protein in FAD mice, and the MDK staining was absent in the knockout mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eg). Additional co-staining with IBA1, a protein marker for microglia\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e, revealed a significant accumulation of microglia around the plaque areas (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eg), in agreement with the observed increase in microglial density and area in the FAD/KO mice. These results underscore that \u003cem\u003eMdk\u003c/em\u003e gene knockout leads to enhanced plaque formation and microglial activation in the FAD mouse model.\u003c/p\u003e \u003cp\u003eTo understand the impact of \u003cem\u003eMdk\u003c/em\u003e knockout in the FAD mice at the molecular level, we analyzed the cortical brain proteome across four genotypes: WT, KO, FAD, and FAD/KO (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ea, \u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e replicates per genotype). Employing a refined tandem-mass-tag coupled with two-dimensional liquid chromatography and tandem mass spectrometry (TMT-LC/LC-MS/MS) platform\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan additionalcitationids=\"CR45\" citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e, we identified 113,297 peptides, corresponding to 9,531 proteins (8,365 genes) with false discovery rate (FDR) below 0.01, which were quantified across all these samples (\u003cb\u003eExtended Data Tables\u0026nbsp;2\u0026ndash;3\u003c/b\u003e). After correcting sample loading bias, principal component analysis (PCA) and clustering analysis clearly separate distinct mouse groups, indicating the high quality of the proteomic data (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eb, \u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ea-\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eb). As expected, MDK protein levels were elevated in FAD mice compared to WT and reduced to noise levels in knockout mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ec). In FAD mice, \u003cem\u003eMdk\u003c/em\u003e deletion led to a significant increase of Aβ peptide levels (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ec).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTo identify the differentially expressed proteins (DEPs) among the four genotypes, we performed an ANOVA analysis using a previously reported method\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e with two criteria: (i) a P-value of less than 0.05, and (ii) a log2 fold change (FC) greater than twice the standard deviation (2 SD) in any of the three pairwise comparisons: WT vs KO, FAD vs WT, or FAD/KO vs FAD (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ec). Following this analysis, a total of 876 DEPs were accepted (\u003cb\u003eExtended Data Table\u0026nbsp;4\u003c/b\u003e), with a final FDR below 0.1 as determined by permutation analysis\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e. We then classified these DEPs into four whole proteome clusters (WPCs) using the weighted gene co-expression network analysis (WGCNA)\u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e, followed by pathway enrichment analysis (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ed, \u003cb\u003eExtended Data Tables\u0026nbsp;4\u0026ndash;5\u003c/b\u003e). In detail, WPC1 (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;460) exhibits a gradual increasing trend across the four genotypes from WT, KO, FAD to FAD/KO. This cluster includes Aβ and Aβ-correlated proteins\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e, such as Ntn1, Ptn, Clu, and Col25a1, as well as some marker proteins for microglia and astrocytes: Trem2, Ctss, Olfml3, Csf1r, Itgb5, Gfap, Aqp4, Pla2g7, Gja1, and Slc1a3\u003csup\u003e49,50\u003c/sup\u003e (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ed), and it is enriched in four representative pathways: APP metabolic process, microglia activation, astrocyte activation and lipid catabolic process (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ee, \u003cb\u003eExtended Data Table\u0026nbsp;6\u003c/b\u003e). In contrast, WPC2 (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;229) shows notable decrease along the four genotypes, related to the pathways of calcium ion transmembrane transport, vesicle-mediated transport in synapse, neurotransmitter secretion, cognition, and G protein-coupled glutamate receptor signaling. Interestingly, this cluster includes the AD risk gene/protein Bin1 that regulates calcium homeostasis and neuronal excitability\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e,\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn addition, both WPC3 (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;84) and WPC4 (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;103) display effects of \u003cem\u003eMdk\u003c/em\u003e knockout that are independent of the FAD genetic background. Proteins in WPC3 decrease in \u003cem\u003eMdk\u003c/em\u003e KO mice and are enriched in four major pathways: neuron fate commitment, Schwann cell differentiation, myelination, and sphingolipid binding (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ee, \u003cb\u003eExtended Data Table\u0026nbsp;6\u003c/b\u003e). For instance, the cluster contains Pou3f1 (also known as Oct-6), which is a major downstream effector of cAMP in Schwann cells and a key transcription factor for myelination in the peripheral nervous system\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e,\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003e. WPC4 primarily consists of proteins that are significantly upregulated due to \u003cem\u003eMdk\u003c/em\u003e knockout, enriched in the pathways of signaling receptor ligand precursor processing, neuropeptide signaling pathway, dendrite terminus, secondary active transmembrane transporter activity and GDP binding. For example, prohormone convertase 1 (Pcsk1) is a critical endopeptidase required for the processing of neurotransmitters and hormones\u003csup\u003e\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e. Overall, the protein alterations found in WPC3 and WPC4 likely reflect the developmental function of midkine, implicating a pleiotropic impact of \u003cem\u003eMdk\u003c/em\u003e knockout. Nevertheless, within WPC1, we observed a distinct increase in Aβ and Aβ-correlated proteins, along with the activation of microglia and astrocytes, supporting that \u003cem\u003eMdk\u003c/em\u003e knockout exacerbates pathological severity.\u003c/p\u003e \u003cp\u003eFurthermore, we validated the enhanced pathology in FAD/KO mice by profiling the detergent-insoluble, aggregated proteome in both FAD and FAD/KO mice, identifying 131,400 peptides from 9,411 unique proteins (8,236 genes, Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003ef, \u003cb\u003eExtended Data Table\u0026nbsp;7\u003c/b\u003e). After performing quality control analyses, such as normalization and PCA (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ee, \u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ef), we found that 450 DEPs were elevated in the aggregated proteome of FAD/KO mice compared to FAD mice (\u003cb\u003eExtended Data\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eg, \u003cb\u003eExtended Data Table\u0026nbsp;7\u003c/b\u003e). Remarkably, the FAD/KO mice showed an accumulation of Aβ and other plaque-associated proteins in the aggregated proteome relative to FAD mice. A heatmap highlights some of these proteins, consistently detected in both the whole and aggregated proteomes, including Ntn1, Apoe, Aqp4, Ptn, Clu, Sulf2, and Col25a1\u003csup\u003e22\u003c/sup\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eg, \u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eh).\u003c/p\u003e \u003cp\u003eIn summary, the knockout of \u003cem\u003eMdk\u003c/em\u003e gene within the FAD mice resulted in an increase in Aβ and Aβ-associated proteins, amyloid plaque formation, and microglial activation. This was substantiated through experiments of western blotting, ELISA, immunostaining of brain tissues, and extensive proteomic profiling of both the whole and aggregated proteomes in the brain.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eRecent proteomics studies of Alzheimer's disease (AD) brains have identified a core set of proteins, including MDK, PTN, NTN1, NTN3, and SFRP1, that share several characteristics: (i) a high correlation with Aβ throughout AD progression; (ii) a prominent presence in the aggregated proteome; and (iii) enrichment in amyloid plaques\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e .However, the role of most of these proteins in AD pathogenesis remains underexplored. We focused on MDK for its potential impact on Aβ fibril assembly in vitro and amyloid plaque development in vivo. Our findings show that MDK disrupts Aβ fibril assembly, and its genetic deletion exacerbates plaque accumulation in the FAD mouse model. Considering the extended prodromal period before clinical AD onset, early Aβ accumulation may activate compensatory mechanisms to mitigate Aβ toxicity. Our research indicates that MDK could be one such factor, offering protective effects against Aβ-induced toxicity and contributing to resistance against amyloid pathology.\u003c/p\u003e \u003cp\u003eMDK protein influences the fibrillation of Aβ40 and Aβ42 peptides, primarily through its inhibitory actions on the elongation of Aβ filaments (\u003cem\u003ek\u003c/em\u003e\u003csub\u003e+\u003c/sub\u003e rate constant) and the secondary nucleation phase of fibrillation (\u003cem\u003ek\u003c/em\u003e\u003csub\u003e2\u003c/sub\u003e rate constant). This influence is demonstrated by AmyloFit analysis of ThT fluorescence data, an approach previously used to study how inhibitors affect specific microscopic steps during the Aβ aggregation\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e,\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e\u003c/sup\u003e. Several other proteins, such as the DNAJB6 and Brichos molecular chaperones, have been found to interfere with Aβ fibrillation through primary and secondary nucleation mechanisms\u003csup\u003e\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e,\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e\u003c/sup\u003e, whereas monomeric α-synuclein can block the secondary nucleation of the Aβ fibrils rather than primary nucleation\u003csup\u003e\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e. Similar to monomeric α-synuclein, MDK might interact with Aβ oligomers rather than Aβ monomer, suppressing the Aβ fibrillation through inhibiting the secondary nucleation. Investigating the Aβ-MDK interaction at an atomic level by cryogenic electron microscopy in future studies will provide more mechanistic insights and could be important for rational design of effective therapeutic strategies in AD pathogenesis.\u003c/p\u003e \u003cp\u003eWhile \u003cem\u003eMdk\u003c/em\u003e knockout's impact on amyloid accumulation in the FAD model can be attributed to its inhibitory effect on Aβ assembly, the \u003cem\u003eMdk\u003c/em\u003e knockout may have a pleiotropic effect. We observed an upregulation of PTN, another member of the midkine/pleiotrophin family. As PTN might have similar function to MDK, this upregulation could act as a compensatory mechanism mitigating the effects of MDK loss on amyloid formation. In addition, MDK has reported to interact with various membrane receptors, including PTPζ (a transmembrane tyrosine phosphatase)\u003csup\u003e\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e\u003c/sup\u003e, LRP-1\u003csup\u003e61\u003c/sup\u003e, integrins (α6β1 and α4β1)\u003csup\u003e\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u003c/sup\u003e, Neuroglycan C\u003csup\u003e\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e\u003c/sup\u003e, ALK (anaplastic lymphoma kinase)\u003csup\u003e\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e, and Notch-2\u003csup\u003e65\u003c/sup\u003e, regulating development, cell migration and inflammation during brain injury\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. Although the role of most of these MDK receptors in AD remains underexplored, LRP-1 is a receptor of the AD risk factor APOE, which regulates lipid hemostasis in AD development\u003csup\u003e\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e\u003c/sup\u003e. In our proteome analysis of \u003cem\u003eMdk\u003c/em\u003e KO mice, although there were no significant changes in the protein levels of these known MDK receptors, we did observe alterations of a subset of proteins (WPC3 and WPC4) resulting from the knockout of \u003cem\u003eMdk\u003c/em\u003e gene, independent of the FAD genetic background. These perturbed proteins might influence amyloid pathology. Nevertheless, our results reveal a potential role of MDK as a resilience factor in the early stage of developing amyloid pathology, offering a promising avenue for therapeutic intervention against the disease's progression.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe thank Dr. Ines Chen for critical readings and comments. We also thank St. Jude Shared Resources and Core Facilities, including Protein Technology Center, Biomolecular NMR Center, Cryo-electron Microscopy and Tomography Center, Cell and Tissue Imaging Center, Animal Research Center, Center for Advanced Genome Engineering, and Center for Proteomics and Metabolomics. This work was partially supported by the National Institutes of Health grants R01AG053987 (J.P.), RF1AG064909 (G.Y. and J.P.), RF1AG068581 (J.P.), U19AG069701 (J.P.), P30CA021765 and the ALSAC foundation. The Banner Sun Health Research Institute Brain and Body Donation Program was supported by the National Institutes of Health grants U24NS072026 (T.G.B), P30AG019610(T.G.B), P30AG072980, the Arizona Department of Health Services, the Arizona Biomedical Research Commission and the Michael J. Fox Foundation for Parkinson’s Research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eContributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eJ.P., P.-C.C., G.Y. M.Z. conceived this project. M.Z., Y.Y, J.Y., A.S.T., R.K., C.R.G., M.T., and S.C. engaged in biophysical experiments. S.Y., Y.H., Z.Wang., H.S., A.H., S.H., Y.J., and P.-C.C. performed biological experiments. P.-C.C., S.M.P.-M., and V.S. generated the \u003cem\u003eMdk\u003c/em\u003e knockout mouse model. S.Y., Z.Wang., L.D., Z.Wu., A.A.H., X.W. contributed to the mass spectrometry-based proteomics analysis. G.E.S. and T.G.B. characterized and provided human brain samples. M.Z., Y.H., P.-C.C. and J.P. wrote the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe mass spectrometry proteomics data were deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifiers PXD046539 (the whole proteome of AD mouse models), and PXD045746 (the aggregated proteome of the mice).\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eAll experiments performed in this study comply with all relevant ethical regulations. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at St Jude Children’s Research Hospital.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistics and reproducibility.\u0026nbsp;\u003c/strong\u003eSample sizes were not predetermined using statistical methods; however, they closely resembled those reported in previous publications\u003csup\u003e68-70\u003c/sup\u003e. While the assumption of normal data distribution was made, formal testing for normality was not conducted. Statistical methods were subsequently employed to estimate p-values, and the analysis of false discovery rate was conducted. No exclusions of animals occurred in the study, and the experiments were not randomized. Animals were utilized whenever available without randomization. The investigators were blinded to genotype information during the quantitation of immunostaining for plaque and microglia.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHuman brain samples\u003c/strong\u003e.\u0026nbsp;Human postmortem brain tissue samples (frontal gyrus) were provided by the Brain and Body Donation Program at Banner Sun Health Research Institute. Clinical and pathological diagnoses were based on the established criteria\u003csup\u003e67\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMouse model.\u0026nbsp;\u003c/strong\u003eAll mice (C57BL/6J) were housed under a 12-h light: 12-h dark cycle at 22-25 °C and 40%-60% humidity. \u003cem\u003eMdk\u0026nbsp;\u003c/em\u003eknockoutmice were generated using CRISPR-Cas9 technology to partially delete coding region in the genome to cause frame shift mutation. Briefly, dual gRNAs were designed with \u003cem\u003ein silico\u003c/em\u003e off-target analysis to determine highly unique spacer sequence with at least 3bp of mismatch to any other site in the mouse genome. In addition, we also consider the targeted region covered among all isoforms, and select CAGE257.MDK.g2 (5’- UGCGGCAUGGGCUUCCGCGA- 3’) and g14 (5’-GCACCUUGCAAUGGACGCGC-3’). Precomplexed ribonucleic proteins (RNPs) consisting of 25 ng/µl of each sgRNA (Synthego) and 50 ng/ µl SpCas9 mRNA (Trilink) were injected into the cytoplasm of C57BL/6J fertilized zygotes and transferred to CD-1 psuedopregnant fosters. Resulting animals were genotyped by targeted next generation sequencing using primers CAGE257.F: 5’-GTGAGGCAGGCCGTGTGACCAAGTG-3’ and CAGE257.R:5’- TGCAGTCGGCTGATGGGAGAGTGGC-3’ and analyzed using CRIS.py as previously described\u003csup\u003e68,69\u003c/sup\u003e Founder animals with out-of-frame mutation were backcrossed to C57BL/6J mice for two generations. A founder carrying a 23bp deletion in exon 2 or 3 of all isoforms was selected for the study. FAD mice (B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax) were obtained from Jackson Laboratory (MMRRC_034848-JAX) and underwent backcrossing with C57BL/6J for 10 generations. \u003cem\u003eFAD/Mdk\u003csup\u003e-/-\u003c/sup\u003e\u003c/em\u003e (FAD/KO)\u0026nbsp;mice were generated by crossing with \u003cem\u003eFAD/Mdk\u003csup\u003e+/-\u003c/sup\u003e\u003c/em\u003e with \u003cem\u003eMdk\u003csup\u003e+/-\u003c/sup\u003e\u003c/em\u003emice. In all mouse experiments, same ratio\u0026nbsp;of male and female animals was utilized.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eWestern blotting.\u0026nbsp;\u003c/strong\u003eProtein lysates underwent separation via 4-20% Tris-Glycine gel and transfer to 0.22 µm nitrocellulose membranes. Blots underwent a 1-h blocking with 3% BSA for MDK or 5% skim milk for other targets. The following primary antibodies were incubated overnight at 4°C: anti-mouse MDK (1:1000, sheep polyclonal, R\u0026amp;D, #AF-7769), anti-Aβ (1:1000, mouse monoclonal, clone 82E1, IBL, #10323), and anti-β-tubulin (1:5000, rat monoclonal, clone YOL1/34, abcam, #ab6161). After three 5-minute washes, blots were exposed to secondary antibodies conjugated with HRP (1:40,000, Jackson ImmunoResearch) for 1 h at room temperature, followed by another three 5-minute washes. Chemiluminescence was developed by using either the SuperSignal West Pico PLUS or Femto substrate (Thermo Fisher Scientific) and subsequent detected by ChemiDoc system (Bio-Rad).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eELISA analysis.\u0026nbsp;\u003c/strong\u003eAβ40 and Aβ42 levels in mouse brain lysate were measured using Meso Scale Diagnostics (MSD) ELISA plate (V-PLEX Aβ Peptide Panel 1 (6E10) Kit)\u003csup\u003e70\u003c/sup\u003e.\u0026nbsp;Briefly, the 96-well plate coated with Aβ40 and Aβ42 antibodies were blocked with blocker diluent for 1 h at room temperature to reduce non-specific protein binding. The plate was washed 3 times with 150\u0026nbsp;µl\u0026nbsp;/well MSD wash buffer. Then 25\u0026nbsp;µl\u0026nbsp;of detection antibody followed by 25\u0026nbsp;µl\u0026nbsp;of diluted standards or mouse brain lysate were loaded and incubated for 2 h. The plate was washed 3 times with 150\u0026nbsp;µl\u0026nbsp;/well wash buffer. Finally, signals were developed by adding 150 µl of 2x read buffer followed with immediately read on the MESO SECTOR S 600 (MSD).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eImmunohistochemistry.\u0026nbsp;\u003c/strong\u003eThe staining was modified from previously report\u003csup\u003e12\u003c/sup\u003e. Briefly, brain tissue samples were fixed with 10% formalin buffer, and embedded in paraffin. 5-10 µm sections were deparaffinized, rehydrated and rinsed with water. Antigen retrieval was performed with 10 mM citric buffer (pH 6.0) with boiled water bath for 20 min and cooled down to room temperature. Endogenous peroxidase activity is blocked by 1% H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u0026nbsp;\u003c/sub\u003ein PBS buffer for 10 min. After rinsed by PBS, sections were then blocked with 5% donkey serum in PBS with 0.3% Triton X-100 (PBST) for 30 min at room temperature followed with primary antibodies diluted with PBST plus 2% BSA and 0.2% skim milk for overnight at 4°C: anti-human MDK, (goat polyclonal, 1:200, R\u0026amp;D, #AF-258-SP), anti-mouse MDK (1:200, sheep polyclonal, R\u0026amp;D, #AF-7769), anti-Aβ (1:100, clone 82E1, IBL, #10323), anti-IBA1 (1:400, rabbit polyclonal, Fujifilm Wako, #019-19741). After washing with PBS, sections were then incubated with secondary antibodies (1:500, Jackson ImmunoResearch) for 1 hour at room temperature. For immunofluorescence staining of Aβ and IBA1, we used Alexa Fluor 488 and Cy3-conjugated secondary antibodies, respectively. For MDK, we went with HRP polymer-conjugated secondary antibodies (Vector Laboratories, # MP-7405). Signal was amplified using TSA-Cy5 (Akoya Biosciences). For chromogenic immunodetection, biotin-conjugated secondary antibodies were used followed with ABC reaction by Vectastain ABC kit (Vector Laboratories, #PK-4000) and developed by 3,3-diaminobenzidine solution (Vector Laboratories, #SK-4100). Images were captured by Zeiss Axioscan.Z1 and Zeiss LSM 780 confocal microscopy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eQuantitation of Aβ plaques and microglia.\u0026nbsp;\u003c/strong\u003eBrain tissue serially sectioned sagittally at 10 μm thickness. Three slides, each representing every 30th section, were utilized for immunohistochemistry followed with imaging captured with Zeiss Axioscan.Z1. QuPath, an open-source software\u003csup\u003e71\u003c/sup\u003e was carried out for quantitation of density and area of Aβ plaques and microglia in an investigator blinded manner.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMDK protein purification.\u0026nbsp;\u003c/strong\u003eThe MDK construct (22-143 aa) was over-expressed in BL21 (DE3) Rosetta 2 cells. A single colony was employed to cultivate a starter culture overnight. Subsequently, 10 ml of the starter culture was utilized to inoculate 1L of 2XYT media, which contained 50 μg/ml Kanamycin and 35 μg/ml Chloramphenicol. The inoculation took place at 37°C, with agitation at 220 rpm, until the cell density reached an OD600 nm of approximately 0.8. The induction of protein over-expression was initiated by adding 0.5 mM Isopropyl β-D-thiogalactopyranoside (IPTG), and the culture was further incubated at 18°C for 16 h. The cells were harvested by centrifugation at 5000 rpm for 15 min at 4 °C and the cell pellet was frozen in - 80°C until used. The cell pellet was resuspended in lysis buffer (20mM HEPES, pH 7.4, 500mM NaCl, 5% glycerol), supplemented with an EDTA-free complete protease inhibitor cocktail tablet (Roche). Disruption was achieved using a cell disruptor (Constant Systems Ltd.) at 20.0 kPSI pressure in 2 rounds of lysis. The resulting lysate was cleared by centrifugation at 20,000 rpm for 30 min at 4 °C and subsequently applied to a gravity column following a 30-minute incubation with pre-equilibrated Ni-NTA resin at 4 °C. The column was then washed by 10 CV of wash buffer A (20mM HEPES pH 7.4, 500mM NaCl, 12.5 mM Imidazole and 5% glycerol), followed by 10 CV of wash buffer B (20mM HEPES pH 7.4, 500mM NaCl, 50 mM Imidazole and 5% glycerol). The protein was eluted with 20mM HEPES pH 7.4, 500mM NaCl, 250 mM Imidazole and 5% glycerol. The eluted fractions were analyzed by loading onto a 4-20% SDS-PAGE gel. Subsequently, the elution fractions were combined, and the His-tag was cleaved from the protein using tobacco etch virus (TEV) protease overnight at 4 °C. The cleaved protein was then further purified by size exclusion chromatography using a Superdex 75 16/600 column (Cytiva) equilibrated with 50 mM Tris-HCl, pH 7.5, 500mM NaCl, and 5% glycerol. Finally, the protein fractions from the column were pooled, concentrated to the desired concentration, flash-frozen in liquid nitrogen, and stored at -80 °C for subsequent experiments.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThT fluorescence assay.\u0026nbsp;\u003c/strong\u003eAβ40 and Aβ42 (rPeptide, #A-1153-1, and #A-1163-2) with a purity of \u0026gt; 97%. Each peptide vial was suspended in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), incubated for an hour to disperse any preexisting aggregates. Further these samples were aliquoted and carefully dried in nitrogen stream and stored in -80°C. Aliquots of purified Aβ species were dissolved in 10 mM NaOH to a concentration of 2 mg/ml followed by 10 min cooling and sonication in an ice water bath for 1 min. The concentration of the final monomeric sample was quantified by nanodrop at 280 nm. Purified MDK was dialyzed overnight in 50 mM Tris-HCl buffer, pH 7.5 and final concentration was determined by absorbance measurements at 280 nm Further, the freshly dissolved Aβ peptides were diluted to 5 µM in absence and presence of different concentrations of purified MDK containing 50 mM Tris-HCl, pH 7.5 buffer containing 20 µM Thioflavin. 100 µl of solution was added into 96-well half area, solid bottom, clear, sterile, microtiter plates and sealed with sealing tape to prevent evaporation. All kinetic experiments were performed at 37˚C under quotient conditions at every 5 min in a Clariostar plate reader (BMG Labtech) using an excitation and emission wavelengths of 440 and 480 nm respectively. All these assays were performed in three replicates. Aggregation kinetics of MDK at different concentrations in the same buffer with fixed ThT concentrations were also recorded.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNMR HSQC\u003c/strong\u003e \u003cstrong\u003eSpectroscopy.\u0026nbsp;\u003c/strong\u003eThe \u003csup\u003e15\u003c/sup\u003eN-labeled Aβ40 and Aβ42 peptides (rPeptide, #A-1101-2 and #A-1102-2) were dissolved in 10mM NaOH to a concentration of 2 mg/ml, followed by 10 min cooling and 1 min sonication in an ice water bath. After aliquoting on ice, the samples were stored in a -80°C freezer. Subsequently, 10 µM of the \u003csup\u003e15\u003c/sup\u003eN-labeled Aβ42 and Aβ40 peptides were incubated with 0, 5, and 10 µM MDK in low-binding tubes (Eppendorf, #0030108434) at 37°C for 24 and 48 h, respectively. The NMR spectra of all these samples including 10 µM monomeric Aβ species were acquired on Bruker Avance 600 MHz or 800 MHz at 278K. The spectrometers are equipped with a triple-resonance cryoprobe, and the data were processed in NMR Pipe\u003csup\u003e72\u003c/sup\u003e.\u0026nbsp;and analyzed using NMRFAM-SPARKY\u003csup\u003e73\u003c/sup\u003e. The backbone resonance assignment of Aβ40 was taken from BMRB (ID: 17795). Binding of MDK to the 15N-labeled Aβ40 and Aβ42 was investigated using two-dimensional (2D) [\u003csup\u003e1\u003c/sup\u003eH-\u003csup\u003e15\u003c/sup\u003eN] so fast HMQC\u003csup\u003e74\u003c/sup\u003e spectrum recorded either with 32 scans or 128 scans with an interscan delay of 0.2 s. The intensity of the peaks from different spectra were quantified, normalized with respect to the highest peak and used in analyzing the data.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCircular dichroism spectroscopy.\u0026nbsp;\u003c/strong\u003eAβ aggregated triplicate samples in the absence and presence of MDK were collected directly from the 96-well plates. CD spectra of monomeric and fibrillated Aβ species (in the absence and presence of MDK) were recorded on a JASCO-1500 Spectrophotometer at a wavelength of 195 - 250 nm with a step size of 0.2 nm, 2 nm bandwidth, and a scan speed of 50 nm/min. CD spectra of MDK alone before and after incubation were also recorded. For each sample, the average of five scans was recorded and background correction was done by subtraction of corresponding buffer spectra. Spectra of native and aggregated MDK were collected with the same parameters at a wavelength of 200 to 250 nm.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNegative stain transmission electron microscopy.\u0026nbsp;\u003c/strong\u003eAβ species alone and reactions involving Aβ together with 10 µM of MDK samples from the kinetic experiments were collected at the end point of the ThT experiments. 400-mesh copper grids (CF400-Cu grids, Electron Microscopy Sciences) were plasma cleaned with an Ar/O2 gas mixture for 10s using Solarus plasma cleaner (Gatan), followed by 5 µl of sample. The samples were allowed to adsorb for 1 min before blotting away the excess liquid, followed by rinsing using Milli Q water and subsequent staining using three successive applications of 2% uranyl acetate. The last round of stain application was allowed to sit for a min before blotting away the excess stain. The grids were air-dried prior to imaging using a 120 kV Talos L120C TEM (Thermo Fisher Scientific) equipped with a CETA detector (TFS).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eImmunogold negative-stain electron microscopy.\u0026nbsp;\u003c/strong\u003eExtraction of Aβ filaments was performed as in the previous report\u003csup\u003e75\u003c/sup\u003e. Aβ filaments were deposited on glow-discharged 400 mesh formvar/carbon coated copper grids (EM Sciences CF400-Cu) for 40 s. Subsequently, the grids were blocked for 10 min with 1% BSA in PBS and incubated with anti-MDK (1:50, goat polyclonal, Bio-Techne, #AF-258-SP). After rinsing with blocking buffer, the grids were incubated with anti-goat IgG conjugated with 10 nm gold particle (1:20, Sigma), followed with wash and stained with 2% uranyl acetate for 1 min. Images were acquired at 11,000x with a Gatan Orius SC200B CCD detector on a Tecnai G2 Spirit at 120 kV.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDetergent extraction for insoluble proteome.\u0026nbsp;\u003c/strong\u003eThe analysis procedure was adapted from a previously published method\u003csup\u003e19\u003c/sup\u003e. Mouse cortices were extracted with Lysis Buffer (50 mM HEPES, pH 7.5, 5 mM EDTA, 1 mM DTT, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% Sarkosyl, 10% glycerol, and 1x Sigma cOmplete Protease Inhibitor Cocktail). Protein lysates were centrifuged at 3000 x g for 5 min at 4°C. The resulting supernatant was subjected to a second centrifugation at 130,000 x g for 1 h at 4°C. The resulting pellet was washed with 50 mM HEPES containing 0.5% sodium deoxycholate and centrifuged at 17,200 x g for 30 min at 4°C. The insoluble pellet was subsequently resuspended in 8 M Urea with 0.5% sodium deoxycholate for proteome profiling.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMass spectrometry-based proteomics.\u0026nbsp;\u003c/strong\u003eWe used an optimized protocol of TMT-LC/LC-MS/MS for deep proteome profiling\u003csup\u003e44,45\u003c/sup\u003e. Protein\u0026nbsp;samples were lysed by homogenization in the lysis buffer (50 mM HEPES, pH 8.5, 8 M urea, and 0.5% sodium deoxycholate), and their concentrations were measured by the BCA assay (Thermo Fisher Scientific, #23227) and confirmed by Coomassie-stained short SDS gels\u0026nbsp;\u003csup\u003e76\u003c/sup\u003e. Quantified protein samples (~0.1 mg per TMT channel) were digested with Lys-C (1:100 w/w, Wako, distributor, #121-05063) for 2 h at 21 ºC, followed by dilution to decrease urea to 2 M and trypsin digestion (1:50 w/w, Promega, #V5113) overnight at 21 ºC. Cys residues were reduced and alkylated by iodoacetamide. The proteolysis was terminated by adding trifluoroacetic acid to 1%. The resulting peptides were desalted with the Sep-Pak C18 cartridges (Waters), TMT-labeled (Thermo Fisher Scientific, #A34808 and A44520), and pooled equally. The pooled peptides were resolved by basic pH reverse phase LC on an XBridge C18 column (3.5 μm beads, 4.6 mm x 25 cm, Waters; buffer A: 10 mM ammonium formate, pH 8.0; buffer B: 95% acetonitrile, 10 mM ammonium formate, pH 8.0, ~2 h gradient, 40-80 concatenated fractions collected)\u003csup\u003e77\u003c/sup\u003e. Each fraction was analyzed by acidic pH LC-MS/MS (75 µm x ~20 cm, 1.9 µm C18 resin from Dr. Maisch GmbH, buffer A: 0.2% formic acid, 5% DMSO; buffer B: buffer A plus 65% acetonitrile, ~1.5 h gradient). The settings of Q Exactive HF Orbitrap MS (Thermo Fisher Scientific) included the MS1 scan (~410-1600 \u003cem\u003em/z\u003c/em\u003e, 60,000 resolution, 1 x 10\u003csup\u003e6\u003c/sup\u003e AGC and 50 ms maximal ion time) and 20 data-dependent MS2 scans (fixed first mass of 120 \u003cem\u003em/z\u003c/em\u003e, 60,000 resolution, 1 x 10\u003csup\u003e5\u003c/sup\u003e AGC, ~110 ms maximal ion time, HCD, 32-35% normalized collision energy, ~1.0 \u003cem\u003em/z\u003c/em\u003e isolation window with 0.3 \u003cem\u003em/z\u003c/em\u003e offset, and ~15 s dynamic exclusion)\u003csup\u003e45\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eThe raw MS data were searched against protein database by the JUMP software (v1.13.4)\u003csup\u003e78\u003c/sup\u003e, which utilizes both pattern matching and \u003cem\u003ede novo\u003c/em\u003e tag scoring to improve the sensitivity and specificity. A composite target/decoy database was used to evaluate FDR in peptide identification\u003csup\u003e79,80\u003c/sup\u003e. The protein target database combined downloaded Swiss-Prot, TrEMBL, and UCSC databases (human: 83,955 entries; mouse: 59,423 entries). Search parameters included precursor/product ion mass tolerance (± 10 ppm), full trypticity, static mass shift (TMT tags of 229.16293 and Cys carbamidomethylation of 57.02146 on cysteine), dynamic mass shift (Met oxidation of 15.99491), two maximal miscleavage sites, and three maximal modification sites. Peptide-spectrum matches (PSMs) were filtered by matching scores and mass accuracy to limit protein FDR below 1%.\u003c/p\u003e\n\u003cp\u003eProteins were quantified from TMT reporter ions based on our published method\u003csup\u003e46\u003c/sup\u003e. Briefly, TMT reporter ion intensities were extracted for each PSM, corrected by isotopic distribution of TMT reagents, filtered to remove poor PSMs (e.g., minimum intensity of 1,000), and adjusted to alleviate sample pooling bias. The relative protein intensities were averaged from all assigned PSMs after removing outliers (e.g., Dixon’s Q-test or generalized extreme Studentized deviate test). Finally, the absolute protein intensities were derived by multiplying the relative intensities by the grand mean of top three abundant PSMs.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePathway enrichment by KEGG and gene ontology databases.\u0026nbsp;\u003c/strong\u003ePathway enrichment analysis was carried out by the JUMPn software (v1.13.0)\u003csup\u003e81\u003c/sup\u003e to identify the biological functions of dysregulated genes/proteins in a given dataset. The analysis was performed using Fisher’s exact test against the Gene Ontology (GO) biological process, molecular function, and cellular component annotations, and KEGG pathway database, separately. The homologous genes between human and mouse were used as the background. The \u003cem\u003ep\u0026nbsp;\u003c/em\u003evalues derived from Fisher’s exact test were further adjusted into FDR using the Benjamini-Hochberg procedure for multiple testing. Enriched pathways with FDR values \u0026lt; 0.05 were considered statistically significant.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProtein-protein interaction (PPI) network analysis.\u0026nbsp;\u003c/strong\u003eThe analysis was performed based on our previously published protocol\u003csup\u003e82\u003c/sup\u003e with modifications. DE genes/proteins were superimposed onto a composite PPI database by combining STRING (v11)\u003csup\u003e83\u003c/sup\u003e, BioPlex (v3.0)\u003csup\u003e84\u003c/sup\u003e, and InWeb_IM (v2016_09_12)\u003csup\u003e85\u003c/sup\u003e.\u0026nbsp;The BioPlex database was developed by the method of affinity purification and mass spectrometry, whereas the STRING and InWeb contain information from various sources. Due to this heterogeneity of PPI interactions, the STRING and InWeb databases were further filtered by the edge score to ensure high quality, with the following rules: (i) only edges with evidence of physical interactions (e.g. through co-IP or yeast two-hybrid) were considered; (ii) edges of high confidence, as filtered by the edge score, with the cutoff determined by best fitting the log-log degree distribution using the scale free criteria\u003csup\u003e86\u003c/sup\u003e. The finally accepted STRING and InWeb databases were combined with BioPlex and the inhibitory postsynaptic density interactome\u003csup\u003e87\u003c/sup\u003e to construct a composite PPI database, which includes 20,485 proteins and 1,152,607 PPI connections. PPI modules were then defined by a three-step procedure: (i) extracting a subnetwork by retaining PPI between two proteins if both were from the DE protein list; (ii) calculating a topologically overlapping measure (TOM)\u003csup\u003e88\u003c/sup\u003e between each pair of proteins for the resulting PPI subnetwork, and (iii) dividing this network into individual modules based on the TOM clustering using the hybrid dynamic tree-cutting method\u003csup\u003e48\u003c/sup\u003e. The biological functions of each PPI module were further obtained using the proteins in each module as the input to perform the pathway enrichment analysis as described above.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eQuantitation and statistical analysis.\u003c/strong\u003e In small-scale analyses, two-tailed unpaired Student’s \u003cem\u003et\u003c/em\u003e-test was used for two-sample comparisons (Graphpad Prism 7.0.5). Proteomics analysis for differentially expressed proteins primarily utilized the limma R package (v3.48.3)\u0026nbsp;\u003csup\u003e89\u003c/sup\u003e in several steps:\u0026nbsp;(i) obtain the protein quantification data from MS as described above, (ii) perform a log transformation of the data\u003csup\u003e90\u003c/sup\u003e, (iii) calculate the \u003cem\u003ep\u003c/em\u003e values by moderated \u003cem\u003et\u003c/em\u003e-test, and FDR values by the Benjamini-Hochberg procedure, using limma R package, (iv) calculate the mean for each protein under different conditions and derive the log2(fold change), (v) fit the log2(fold change) data of all proteins to a Gaussian distribution to generate a 'global' standard deviation value. Statistically significant changes were typically determined using an \u003cem\u003eP\u003c/em\u003e value cutoff of 0.05 and a log2 (fold change) cutoff equivalent to two standard deviations.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAlzheimer's_Association. 2023 Alzheimer's disease facts and figures. \u003cem\u003eAlzheimers Dement\u003c/em\u003e 19, 1598\u0026ndash;1695, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/alz.13016\u003c/span\u003e\u003cspan address=\"10.1002/alz.13016\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBellenguez, C., Grenier-Boley, B. \u0026amp; Lambert, J. C. Genetics of Alzheimer's disease: where we are, and where we are going. Curr Opin Neurobiol 61, 40\u0026ndash;48, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.conb.2019.11.024\u003c/span\u003e\u003cspan address=\"10.1016/j.conb.2019.11.024\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBellenguez, C. \u003cem\u003eet al.\u003c/em\u003e New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 54, 412\u0026ndash;436, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41588-022-01024-z\u003c/span\u003e\u003cspan address=\"10.1038/s41588-022-01024-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWightman, D. P. \u003cem\u003eet al.\u003c/em\u003e A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 53, 1276\u0026ndash;1282, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41588-021-00921-z\u003c/span\u003e\u003cspan address=\"10.1038/s41588-021-00921-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHardy, J. \u0026amp; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353\u0026ndash;356 (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBallatore, C., Lee, V. M. \u0026amp; Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663\u0026ndash;672 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNeumann, M. \u003cem\u003eet al.\u003c/em\u003e Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130\u0026ndash;133 (2006).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNelson, P. T. \u003cem\u003eet al.\u003c/em\u003e Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503\u0026ndash;1527, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/brain/awz099\u003c/span\u003e\u003cspan address=\"10.1093/brain/awz099\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai, B. \u003cem\u003eet al.\u003c/em\u003e U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A 110, 16562\u0026ndash;16567, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1073/pnas.1310249110\u003c/span\u003e\u003cspan address=\"10.1073/pnas.1310249110\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai, B. \u003cem\u003eet al.\u003c/em\u003e Integrated Approaches for Analyzing U1-70K Cleavage in Alzheimer's Disease. J Proteome Res 13, 4526\u0026ndash;4534, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/pr5003593\u003c/span\u003e\u003cspan address=\"10.1021/pr5003593\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHales, C. M. \u003cem\u003eet al.\u003c/em\u003e U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegener 9, 15, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/1750-1326-9-15\u003c/span\u003e\u003cspan address=\"10.1186/1750-1326-9-15\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen, P. C. \u003cem\u003eet al.\u003c/em\u003e Alzheimer's disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment. Nat Aging 2, 923\u0026ndash;940, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s43587-022-00290-0\u003c/span\u003e\u003cspan address=\"10.1038/s43587-022-00290-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZaman, M. \u003cem\u003eet al.\u003c/em\u003e Dissecting Detergent-Insoluble Proteome in Alzheimer's Disease by TMTc-Corrected Quantitative Mass Spectrometry. Mol Cell Proteomics 22, 100608, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.mcpro.2023.100608\u003c/span\u003e\u003cspan address=\"10.1016/j.mcpro.2023.100608\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Dyck, C. H. \u003cem\u003eet al.\u003c/em\u003e Lecanemab in Early Alzheimer's Disease. N Engl J Med 388, 9\u0026ndash;21, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa2212948\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa2212948\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSims, J. R. \u003cem\u003eet al.\u003c/em\u003e Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512\u0026ndash;527, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jama.2023.13239\u003c/span\u003e\u003cspan address=\"10.1001/jama.2023.13239\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai, B. \u003cem\u003eet al.\u003c/em\u003e Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer\u0026rsquo;s Disease Progression. Neuron 105, 975\u0026ndash;991 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang, H. \u003cem\u003eet al.\u003c/em\u003e Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. Mol Neurodegener 15, 43, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s13024-020-00384-6\u003c/span\u003e\u003cspan address=\"10.1186/s13024-020-00384-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHigginbotham, L. \u003cem\u003eet al.\u003c/em\u003e Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Sci Adv 6, eaaz9360, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/sciadv.aaz9360\u003c/span\u003e\u003cspan address=\"10.1126/sciadv.aaz9360\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJohnson, E. C. B. \u003cem\u003eet al.\u003c/em\u003e Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat Neurosci 25, 213\u0026ndash;225, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41593-021-00999-y\u003c/span\u003e\u003cspan address=\"10.1038/s41593-021-00999-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSathe, G. \u003cem\u003eet al.\u003c/em\u003e Quantitative proteomic analysis of the frontal cortex in Alzheimer's disease. J Neurochem 156, 988\u0026ndash;1002, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/jnc.15116\u003c/span\u003e\u003cspan address=\"10.1111/jnc.15116\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoberts, J. A. \u003cem\u003eet al.\u003c/em\u003e A brain proteomic signature of incipient Alzheimer's disease in young APOE epsilon4 carriers identifies novel drug targets. Sci Adv 7, eabi8178, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/sciadv.abi8178\u003c/span\u003e\u003cspan address=\"10.1126/sciadv.abi8178\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai, B. \u003cem\u003eet al.\u003c/em\u003e Proteomic landscape of Alzheimer's disease: novel insights into pathogenesis and biomarker discovery. Mol Neurodegener 16, 55 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAskenazi, M. \u003cem\u003eet al.\u003c/em\u003e Compilation of reported protein changes in the brain in Alzheimer's disease. Nat Commun 14, 4466, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41467-023-40208-x\u003c/span\u003e\u003cspan address=\"10.1038/s41467-023-40208-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiao, L. \u003cem\u003eet al.\u003c/em\u003e Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 279, 37061\u0026ndash;37068 (2004).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXiong, F., Ge, W. \u0026amp; Ma, C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimers Dement 15, 429\u0026ndash;440, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jalz.2018.10.006\u003c/span\u003e\u003cspan address=\"10.1016/j.jalz.2018.10.006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDrummond, E. \u003cem\u003eet al.\u003c/em\u003e The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome. Acta Neuropathol Commun 10, 53, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s40478-022-01356-1\u003c/span\u003e\u003cspan address=\"10.1186/s40478-022-01356-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRahman, M. M. \u0026amp; Lendel, C. Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology. Mol Neurodegener 16, 59, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s13024-021-00465-0\u003c/span\u003e\u003cspan address=\"10.1186/s13024-021-00465-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoss-Munro, E. \u003cem\u003eet al.\u003c/em\u003e Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury. \u003cem\u003eFront Neurol\u003c/em\u003e 11, 568814, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fneur.2020.568814\u003c/span\u003e\u003cspan address=\"10.3389/fneur.2020.568814\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYasuhara, O. \u003cem\u003eet al.\u003c/em\u003e Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease. Biochem Biophys Res Commun 192, 246\u0026ndash;251, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1006/bbrc.1993.1406\u003c/span\u003e\u003cspan address=\"10.1006/bbrc.1993.1406\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1993).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuramatsu, H. \u003cem\u003eet al.\u003c/em\u003e Midkine as a factor to counteract the deposition of amyloid beta-peptide plaques: in vitro analysis and examination in knockout mice. Int Arch Med 4, 1, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/1755-7682-4-1\u003c/span\u003e\u003cspan address=\"10.1186/1755-7682-4-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOakley, H. \u003cem\u003eet al.\u003c/em\u003e Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129\u0026ndash;10140, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1523/JNEUROSCI.1202-06.2006\u003c/span\u003e\u003cspan address=\"10.1523/JNEUROSCI.1202-06.2006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2006).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLeVine, H., 3rd. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2, 404\u0026ndash;410, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/pro.5560020312\u003c/span\u003e\u003cspan address=\"10.1002/pro.5560020312\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1993).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeisl, G. \u003cem\u003eet al.\u003c/em\u003e Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat Protoc 11, 252\u0026ndash;272, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nprot.2016.010\u003c/span\u003e\u003cspan address=\"10.1038/nprot.2016.010\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang, Y. \u003cem\u003eet al.\u003c/em\u003e Cryo-EM structures of amyloid-beta 42 filaments from human brains. Science 375, 167\u0026ndash;172, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/science.abm7285\u003c/span\u003e\u003cspan address=\"10.1126/science.abm7285\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKollmer, M. \u003cem\u003eet al.\u003c/em\u003e Cryo-EM structure and polymorphism of Abeta amyloid fibrils purified from Alzheimer's brain tissue. Nat Commun 10, 4760, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41467-019-12683-8\u003c/span\u003e\u003cspan address=\"10.1038/s41467-019-12683-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLu, J. X. \u003cem\u003eet al.\u003c/em\u003e Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154, 1257\u0026ndash;1268, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cell.2013.08.035\u003c/span\u003e\u003cspan address=\"10.1016/j.cell.2013.08.035\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSawaya, M. R., Hughes, M. P., Rodriguez, J. A., Riek, R. \u0026amp; Eisenberg, D. S. The expanding amyloid family: Structure, stability, function, and pathogenesis. Cell 184, 4857\u0026ndash;4873, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cell.2021.08.013\u003c/span\u003e\u003cspan address=\"10.1016/j.cell.2021.08.013\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang, Y. \u003cem\u003eet al.\u003c/em\u003e Cryo-EM structures of amyloid-beta filaments with the Arctic mutation (E22G) from human and mouse brains. Acta Neuropathol 145, 325\u0026ndash;333, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00401-022-02533-1\u003c/span\u003e\u003cspan address=\"10.1007/s00401-022-02533-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e\u003cem\u003ebiorxiv\u003c/em\u003e, DOI: 10.1101/2021.1110.1104.463034, doi:10.1101/2021.10.04.463034 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoche, J., Shen, Y., Lee, J. H., Ying, J. \u0026amp; Bax, A. Monomeric Aβ(1\u0026ndash;40) and Aβ(1\u0026ndash;42) Peptides in Solution Adopt Very Similar Ramachandran Map Distributions That Closely Resemble Random Coil. Biochemistry 55, 762\u0026ndash;775, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/acs.biochem.5b01259\u003c/span\u003e\u003cspan address=\"10.1021/acs.biochem.5b01259\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWallin, C. \u003cem\u003eet al.\u003c/em\u003e The Neuronal Tau Protein Blocks in Vitro Fibrillation of the Amyloid-β (Aβ) Peptide at the Oligomeric Stage. J Am Chem Soc 140, 8138\u0026ndash;8146, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/jacs.7b13623\u003c/span\u003e\u003cspan address=\"10.1021/jacs.7b13623\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIto, D. \u003cem\u003eet al.\u003c/em\u003e Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57, 1\u0026ndash;9, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0169-328x(98)00040-0\u003c/span\u003e\u003cspan address=\"10.1016/s0169-328x(98)00040-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1998).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchwabenland, M. \u003cem\u003eet al.\u003c/em\u003e Analyzing microglial phenotypes across neuropathologies: a practical guide. Acta Neuropathol 142, 923\u0026ndash;936, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00401-021-02370-8\u003c/span\u003e\u003cspan address=\"10.1007/s00401-021-02370-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai, B. \u003cem\u003eet al.\u003c/em\u003e Deep Profiling of Proteome and Phosphoproteome by Isobaric Labeling, Extensive Liquid Chromatography, and Mass Spectrometry. Methods Enzymol 585, 377\u0026ndash;395 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang, Z. \u003cem\u003eet al.\u003c/em\u003e 27-plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease. Anal Chem 92, 7162\u0026ndash;7170 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNiu, M. \u003cem\u003eet al.\u003c/em\u003e Extensive Peptide Fractionation and y1 Ion-Based Interference Detection Method for Enabling Accurate Quantification by Isobaric Labeling and Mass Spectrometry. Anal Chem 89, 2956\u0026ndash;2963, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/acs.analchem.6b04415\u003c/span\u003e\u003cspan address=\"10.1021/acs.analchem.6b04415\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXie, Y., Pan, W. \u0026amp; Khodursky, A. B. A note on using permutation-based false discovery rate estimates to compare different analysis methods for microarray data. Bioinformatics 21, 4280\u0026ndash;4288, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/bioinformatics/bti685\u003c/span\u003e\u003cspan address=\"10.1093/bioinformatics/bti685\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLangfelder, P. \u0026amp; Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/1471-2105-9-559\u003c/span\u003e\u003cspan address=\"10.1186/1471-2105-9-559\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSousa, C. \u003cem\u003eet al.\u003c/em\u003e Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures. EMBO Rep 19, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.15252/embr.201846171\u003c/span\u003e\u003cspan address=\"10.15252/embr.201846171\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, Y. \u003cem\u003eet al.\u003c/em\u003e Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37\u0026ndash;53, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.neuron.2015.11.013\u003c/span\u003e\u003cspan address=\"10.1016/j.neuron.2015.11.013\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSaha, O. \u003cem\u003eet al.\u003c/em\u003e The Alzheimer's disease risk gene BIN1 regulates activity-dependent gene expression in human-induced glutamatergic neurons. Molecular psychiatry, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41380-024-02502-y\u003c/span\u003e\u003cspan address=\"10.1038/s41380-024-02502-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVoskobiynyk, Y. \u003cem\u003eet al.\u003c/em\u003e Alzheimer's disease risk gene BIN1 induces Tau-dependent network hyperexcitability. Elife 9, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7554/eLife.57354\u003c/span\u003e\u003cspan address=\"10.7554/eLife.57354\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJaegle, M. \u003cem\u003eet al.\u003c/em\u003e The POU factor Oct-6 and Schwann cell differentiation. Science 273, 507\u0026ndash;510, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/science.273.5274.507\u003c/span\u003e\u003cspan address=\"10.1126/science.273.5274.507\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1996).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBermingham, J. R., Jr. \u003cem\u003eet al.\u003c/em\u003e Tst-1/Oct-6/SCIP regulates a unique step in peripheral myelination and is required for normal respiration. Genes Dev 10, 1751\u0026ndash;1762, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1101/gad.10.14.1751\u003c/span\u003e\u003cspan address=\"10.1101/gad.10.14.1751\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1996).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStijnen, P., Ramos-Molina, B., O'Rahilly, S. \u0026amp; Creemers, J. W. PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders. Endocr Rev 37, 347\u0026ndash;371, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1210/er.2015-1117\u003c/span\u003e\u003cspan address=\"10.1210/er.2015-1117\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMunke, A. \u003cem\u003eet al.\u003c/em\u003e Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. Proc Natl Acad Sci U S A 114, 6444\u0026ndash;6449, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1073/pnas.1700407114\u003c/span\u003e\u003cspan address=\"10.1073/pnas.1700407114\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eM\u0026aring;nsson, C. \u003cem\u003eet al.\u003c/em\u003e Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (Aβ42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. J Biol Chem 289, 31066\u0026ndash;31076, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1074/jbc.M114.595124\u003c/span\u003e\u003cspan address=\"10.1074/jbc.M114.595124\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCohen, S. I. A. \u003cem\u003eet al.\u003c/em\u003e A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat Struct Mol Biol 22, 207\u0026ndash;213, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nsmb.2971\u003c/span\u003e\u003cspan address=\"10.1038/nsmb.2971\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChia, S. \u003cem\u003eet al.\u003c/em\u003e Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates. Proc Natl Acad Sci U S A 114, 8005\u0026ndash;8010, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1073/pnas.1700239114\u003c/span\u003e\u003cspan address=\"10.1073/pnas.1700239114\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaeda, N. \u003cem\u003eet al.\u003c/em\u003e A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem 274, 12474\u0026ndash;12479, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1074/jbc.274.18.12474\u003c/span\u003e\u003cspan address=\"10.1074/jbc.274.18.12474\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1999).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuramatsu, H. \u003cem\u003eet al.\u003c/em\u003e LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 270, 936\u0026ndash;941, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1006/bbrc.2000.2549\u003c/span\u003e\u003cspan address=\"10.1006/bbrc.2000.2549\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuramatsu, H. \u003cem\u003eet al.\u003c/em\u003e alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 117, 5405\u0026ndash;5415, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1242/jcs.01423\u003c/span\u003e\u003cspan address=\"10.1242/jcs.01423\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2004).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIchihara-Tanaka, K., Oohira, A., Rumsby, M. \u0026amp; Muramatsu, T. Neuroglycan C is a novel midkine receptor involved in process elongation of oligodendroglial precursor-like cells. J Biol Chem 281, 30857\u0026ndash;30864, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1074/jbc.M602228200\u003c/span\u003e\u003cspan address=\"10.1074/jbc.M602228200\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2006).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStoica, G. E. \u003cem\u003eet al.\u003c/em\u003e Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277, 35990\u0026ndash;35998, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1074/jbc.M205749200\u003c/span\u003e\u003cspan address=\"10.1074/jbc.M205749200\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang, Y. \u003cem\u003eet al.\u003c/em\u003e Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle 7, 1613\u0026ndash;1622, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.4161/cc.7.11.5952\u003c/span\u003e\u003cspan address=\"10.4161/cc.7.11.5952\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. \u0026amp; Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15, 501\u0026ndash;518, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41582-019-0228-7\u003c/span\u003e\u003cspan address=\"10.1038/s41582-019-0228-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeach, T. G. \u003cem\u003eet al.\u003c/em\u003e Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 35, 354\u0026ndash;389, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/neup.12189\u003c/span\u003e\u003cspan address=\"10.1111/neup.12189\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eConnelly, J. P. \u0026amp; Pruett-Miller, S. M. CRIS.py: A Versatile and High-throughput Analysis Program for CRISPR-based Genome Editing. Sci Rep 9, 4194, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-019-40896-w\u003c/span\u003e\u003cspan address=\"10.1038/s41598-019-40896-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNarina, S., Connelly, J. P. \u0026amp; Pruett-Miller, S. M. High-Throughput Analysis of CRISPR-Cas9 Editing Outcomes in Cell and Animal Models Using CRIS.py. Methods Mol Biol 2631, 155\u0026ndash;182, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/978-1-0716-2990-1_6\u003c/span\u003e\u003cspan address=\"10.1007/978-1-0716-2990-1_6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePetit, D. \u003cem\u003eet al.\u003c/em\u003e Aβ profiles generated by Alzheimer\u0026rsquo;s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular psychiatry 27, 2821\u0026ndash;2832, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41380-022-01518-6\u003c/span\u003e\u003cspan address=\"10.1038/s41380-022-01518-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBankhead, P. \u003cem\u003eet al.\u003c/em\u003e QuPath: Open source software for digital pathology image analysis. Sci Rep 7, 16878, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-017-17204-5\u003c/span\u003e\u003cspan address=\"10.1038/s41598-017-17204-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDelaglio, F. \u003cem\u003eet al.\u003c/em\u003e NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6, 277\u0026ndash;293, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/bf00197809\u003c/span\u003e\u003cspan address=\"10.1007/bf00197809\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1995).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee, W., Tonelli, M. \u0026amp; Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 31, 1325\u0026ndash;1327, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/bioinformatics/btu830\u003c/span\u003e\u003cspan address=\"10.1093/bioinformatics/btu830\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchanda, P., Kupce, E. \u0026amp; Brutscher, B. SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR 33, 199\u0026ndash;211, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s10858-005-4425-x\u003c/span\u003e\u003cspan address=\"10.1007/s10858-005-4425-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang, Y. \u003cem\u003eet al.\u003c/em\u003e Cryo-EM structures of amyloid-β 42 filaments from human brains. Science 375, 167\u0026ndash;172, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/science.abm7285\u003c/span\u003e\u003cspan address=\"10.1126/science.abm7285\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu, P., Duong, D. M. \u0026amp; Peng, J. Systematical Optimization of Reverse-Phase Chromatography for Shotgun Proteomics. J Proteome Res 8, 3944\u0026ndash;3950, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/pr900251d\u003c/span\u003e\u003cspan address=\"10.1021/pr900251d\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang, H. \u003cem\u003eet al.\u003c/em\u003e Systematic optimization of long gradient chromatography mass spectrometry for deep analysis of brain proteome. J Proteome Res 14, 829\u0026ndash;838, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/pr500882h\u003c/span\u003e\u003cspan address=\"10.1021/pr500882h\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang, X. \u003cem\u003eet al.\u003c/em\u003e JUMP: a tag-based database search tool for peptide identification with high sensitivity and accuracy. Mol Cell Proteomics 13, 3663\u0026ndash;3673, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1074/mcp.O114.039586\u003c/span\u003e\u003cspan address=\"10.1074/mcp.O114.039586\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeng, J., Elias, J. E., Thoreen, C. C., Licklider, L. J. \u0026amp; Gygi, S. P. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res 2, 43\u0026ndash;50 (2003).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eElias, J. E. \u0026amp; Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4, 207\u0026ndash;214 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVanderwall, D. \u003cem\u003eet al.\u003c/em\u003e JUMPn: A Streamlined Application for Protein Co-Expression Clustering and Network Analysis in Proteomics. J Vis Exp 176, 10.3791/62796, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3791/62796\u003c/span\u003e\u003cspan address=\"10.3791/62796\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTan, H. \u003cem\u003eet al.\u003c/em\u003e Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation. Immunity 46, 488\u0026ndash;503, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.immuni.2017.02.010\u003c/span\u003e\u003cspan address=\"10.1016/j.immuni.2017.02.010\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSzklarczyk, D. \u003cem\u003eet al.\u003c/em\u003e STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, D447-452, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/nar/gku1003\u003c/span\u003e\u003cspan address=\"10.1093/nar/gku1003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuttlin, E. L. \u003cem\u003eet al.\u003c/em\u003e The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 162, 425\u0026ndash;440, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cell.2015.06.043\u003c/span\u003e\u003cspan address=\"10.1016/j.cell.2015.06.043\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, T. \u003cem\u003eet al.\u003c/em\u003e A scored human protein-protein interaction network to catalyze genomic interpretation. Nat Methods 14, 61\u0026ndash;64, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nmeth.4083\u003c/span\u003e\u003cspan address=\"10.1038/nmeth.4083\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarabasi, A. L. \u0026amp; Oltvai, Z. N. Network biology: understanding the cell's functional organization. Nat Rev Genet 5, 101\u0026ndash;113, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrg1272\u003c/span\u003e\u003cspan address=\"10.1038/nrg1272\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2004).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUezu, A. \u003cem\u003eet al.\u003c/em\u003e Identification of an elaborate complex mediating postsynaptic inhibition. Science 353, 1123\u0026ndash;1129, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/science.aag0821\u003c/span\u003e\u003cspan address=\"10.1126/science.aag0821\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRavasz, E., Somera, A. L., Mongru, D. A., Oltvai, Z. N. \u0026amp; Barabasi, A. L. Hierarchical organization of modularity in metabolic networks. Science 297, 1551\u0026ndash;1555, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/science.1073374\u003c/span\u003e\u003cspan address=\"10.1126/science.1073374\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRitchie, M. E. \u003cem\u003eet al.\u003c/em\u003e limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/nar/gkv007\u003c/span\u003e\u003cspan address=\"10.1093/nar/gkv007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMertens, B. J. A. Transformation, Normalization, and Batch Effect in the Analysis of Mass Spectrometry Data for Omics Studies. \u003cem\u003eStatistical Analysis of Proteomics, Metabolomics, and Lipidomics Data Using Mass Spectrometry\u003c/em\u003e, 1\u0026ndash;21 (2016).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-4361125/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4361125/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eProteomic profiling of Alzheimer's disease (AD) brains has identified numerous understudied proteins, including midkine (MDK), that are highly upregulated and correlated with Aβ since the early disease stage, but their roles in disease progression are not fully understood. Here we present that MDK attenuates Aβ assembly and influences amyloid formation in the 5xFAD amyloidosis mouse model. MDK protein mitigates fibril formation of both Aβ40 and Aβ42 peptides in Thioflavin T fluorescence assay, circular dichroism, negative stain electron microscopy, and NMR analysis. Knockout of \u003cem\u003eMdk\u003c/em\u003egene in 5xFAD increases amyloid formation and microglial activation. Further comprehensive mass spectrometry-based profiling of whole proteome and aggregated proteome in these mouse models indicates significant accumulation of Aβ and Aβ-correlated proteins, along with microglial components. Thus, our structural and mouse model studies reveal a protective role of MDK in counteracting amyloid pathology in Alzheimer's disease.\u003c/p\u003e","manuscriptTitle":"Midkine Attenuates Aβ Fibril Assembly and Amyloid Plaque Formation","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-06-07 17:30:45","doi":"10.21203/rs.3.rs-4361125/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"nature-structural-and-molecular-biology","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"nsmb","sideBox":"Learn more about [Nature Structural \u0026 Molecular Biology](http://www.nature.com/nsmb/)","snPcode":"","submissionUrl":"","title":"Nature Structural \u0026 Molecular Biology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature Research","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"219346de-92f9-45e1-9473-1de720186a80","owner":[],"postedDate":"June 7th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":32016633,"name":"Biological sciences/Chemical biology/Proteomics/Protein\u0026#x2013;protein interaction networks"},{"id":32016634,"name":"Biological sciences/Structural biology/NMR spectroscopy/Solution-state NMR"}],"tags":[],"updatedAt":"2025-08-23T07:13:01+00:00","versionOfRecord":{"articleIdentity":"rs-4361125","link":"https://doi.org/10.1038/s41594-025-01657-8","journal":{"identity":"nature-structural-and-molecular-biology","isVorOnly":false,"title":"Nature Structural \u0026 Molecular Biology"},"publishedOn":"2025-08-21 04:00:00","publishedOnDateReadable":"August 21st, 2025"},"versionCreatedAt":"2024-06-07 17:30:45","video":"","vorDoi":"10.1038/s41594-025-01657-8","vorDoiUrl":"https://doi.org/10.1038/s41594-025-01657-8","workflowStages":[]},"version":"v1","identity":"rs-4361125","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4361125","identity":"rs-4361125","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}